

Date: March 17, 2000

Page 1

**TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 USC 371**

International Application No.: PCT/BE98/00141
International Filing Date: September 28, 1998
Priority Date Claimed: September 26, 1997
Title of Invention: GENETIC SEQUENCES, DIAGNOSTIC AND/OR QUANTIFICATION
METHODS AND DEVICES FOR THE IDENTIFICATION OF *STAPHYLOCOCCI* STRAINS
Applicant(s) for DO/EO/US: Pascal Vannuffel, Jean-Luc Gala

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. (X) This is a **FIRST** submission of items concerning a filing under 35 USC 371.
2. (X) This express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 USC 371(b) and PCT Articles 22 and 39(1).
3. (X) A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
4. (X) A copy of the International Application as filed (35 USC 371(c)(2))
 - a) () is transmitted herewith (required only if not transmitted by the International Bureau).
 - b) (X) has been transmitted by the International Bureau.
 - c) () is not required, as the application was filed in the United States Receiving Office (RO/US).
5. (X) Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3))
 - a) () are transmitted herewith (required only if not transmitted by the International Bureau).
 - b) () have been transmitted by the International Bureau.
 - c) () have not been made; however, the time limit for making such amendments has NOT expired.
 - d) (X) have not been made and will not be made.
6. (X) A copy of the International Preliminary Examination Report with any annexes thereto, such as any amendments made under PCT Article 34.
7. (X) A **FIRST** preliminary amendment.
8. (X) International Application as published.
9. (X) PCT Form PCT/IPEA/402.
10. (X) PCT Form PCT/IB/308.
11. (X) PCT request form.
12. (X) A return prepaid postcard.

U.S. Application No.

International Application No.
PCT/BE98/00141

09/509234

Attorney Docket No.
VANM145.001APC

Date: March 17, 2000

416 Rec'd PCT/PTO 17 MAR 2000

Page 2

13. (X) The following fees are submitted:

				FEES
BASIC FEE				\$840
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	32 - 20 =	12 ×	\$18	\$216
Independent Claims	4 - 3 =	1 ×	\$78	\$78
TOTAL FEES ENCLOSED				\$1134

14. (X) The fee for later submission of the signed oath or declaration set forth in 37 CFR 1.492(e) will be paid upon submission of the declaration.
15. (X) A check in the amount of \$840 to cover the above fees is enclosed.
16. (X) The Commissioner is hereby authorized to charge only those additional fees which may be required, now or in the future, to avoid abandonment of the application, or credit any overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

KNOBBE, MARTENS, OLSON & BEAR, LLP
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660


Signature

Daniel E. Altman
Printed Name

34,115
Registration Number

VANM145.001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Vannuffel, et al.)
)
Int'l)
Appl. No. : PCT/BE98/00141)
)
Int'l Filing)
Date : September 28, 1998)
)
For : GENETIC SEQUENCES,)
DIAGNOSTIC AND/OR)
QUANTIFICATION)
METHODS AND DEVICES)
FOR THE IDENTIFICATION)
OF STAPHYLOCOCCI)
STRAINS)
)
Examiner : Unknown)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Preliminary to examination on the merits, please amend the above-captioned U.S. National Phase application as follows:

IN THE SPECIFICATION

On page 1, at line 11, after the Title of the Invention and before the Field of the Invention, please insert --This application is the U.S. National Phase under 35 U.S.C. § 371 of International Application PCT/BE98/00141, filed September 28, 1998, which claims priority of European Application 97870146.4, filed September 26, 1997.--.

On page 21, line 1, please delete the word "CLAIMS" and substitute in its place --WHAT IS CLAIMED IS:--.

Appl. No. : PCT/BE98/00141
Date : September 28, 1998

IN THE CLAIMS

Please cancel claims 3-4, 12 and 24-30.

Please amend the remaining claims as follows:

1. (Amended) An isolated or purified [Oligonucleotide]oligonucleotide for the specific identification of *Staphylococci* species, comprising [having] a nucleotide sequence [comprising between]of about 15 [and]to 350 base pairs[, preferably between 17 and 250 base pairs, and which presents less than 50% homology with] of the “consensus” femA nucleotide sequence [(CNS) of Fig. 3]SEQ ID NO:1.

2. (Amended) The [Oligonucleotide]oligonucleotide according to claim 1 [for the specific identification of *Staphylococci* species having]comprising a nucleotide sequence [comprising between 15 and 350 base pairs, preferably between]of about 17 [and]to 250 base pairs[, and which presents less than 40% homology with]of [the “consensus” femA nucleotide sequence (CNS) of Fig. 3]SEQ ID NO:1.

5. (Amended) The [Oligonucleotide]oligonucleotide according to claim 1, [being a primer which]wherein the nucleotide sequence [has between]comprises about 15 [and]to 45 base pairs[, preferably between 17 and 25 base pairs].

6. (Amended) The [Oligonucleotide]oligonucleotide according to Claim 5, which is selected from the group consisting of [the following nucleotide sequences:

- ACAGCAGATGACATCATT
- TAATGAAAGAAATGTGCTTA
- ACACAACCTTCAATTAGAAC
- AGTATTAGCAAATGCGG
- ATGCATATTTTCCGTAA
- CAGCAGATGACATCATT
- CATCTAAAGATATATTAAATGGA
- AGTATTAGCAAATGCGGGTCAC
- CAACACAACCTTCAATTAGAA] SEQ ID NOS:45-53.

7. (Amended) [Couple of]Two or more isolated or purified oligonucleotides for the specific amplification of *Staphylococci* species [consisting of]comprising [two different]at least one nucleotide sequence[s having between] of about 15 [and]to 45 base pairs[, preferably between 17 and 25 base pairs, and which present] more than 60% [homology with]homologous to [the “consensus” femA nucleotide sequence (CNS) of Fig. 3]SEQ ID NO:1 and/or [consisting of one nucleotide sequence] at least one oligonucleotide [having

Appl. No. : PCT/BE98/00141
Date : September 28, 1998

between] about 15 [and] to 45 base pairs[, preferably between 17 and 25 base pairs, and which presents] more than 60% [homology with] homologous to [the “consensus” *femA* nucleotide sequence (CNS) of Fig. 3 and the oligonucleotide of Claim 6]SEQ ID NOS:1, and 45-53.

8. (Amended) [Couple of] The oligonucleotides according to Claim [1 for the specific amplification of *Staphylococci* species, consisting of two different nucleotide sequences having between 15 and 45 base pairs, preferably between 17 and 25 base pairs, and which present more than 70% homology with the “consensus” *femA* nucleotide sequence (CNS) of Fig. 3 or consisting of one nucleotide sequence having between 15 and 45 base pairs, preferably between 17 and 25 base pairs, and which presents more than 70% homology with the “consensus” *femA* nucleotide sequence (CNS) of Fig. 3 and the oligonucleotide of Claim 1]7 wherein said oligonucleotides have more than 70% homology to SEQ ID NOS:1, and 45-53.

9. (Amended) [Couple of] The oligonucleotides according to Claim [7 or 8 for the specific amplification of *Staphylococci* species, consisting of two different nucleotide sequences having between 15 and 45 base pairs, preferably between 17 and 25 base pairs, and which present more than 80% homology with the “consensus” *femA* nucleotide sequence (CNS) of Fig. 3 or consisting of one nucleotide sequence (CNS) of Fig. 3 or consisting of one nucleotide sequence having between 15 and 45 base pairs, preferably between 17 and 25 base pairs, and which presents more than 80% homology with the “consensus” *femA* nucleotide sequence (CNS) of Fig. 3 and the oligonucleotide of Claim 1]8 wherein said oligonucleotides have more than 80% homology to SEQ ID NOS:1, and 45-53.

10. (Amended) [Couple of] The oligonucleotides according to [any one of the Claims 7 to 9 for the specific amplification of *Staphylococci* species, consisting of two different nucleotide sequences having between 15 and 45 base pairs, preferably between 17 and 25 base pairs, and which present more than 90% homology with the “consensus” *femA* nucleotide sequence (CNS) of Fig. 3 or consisting of one nucleotide sequence having between 15 and 45 base pairs, preferably between 17 and 25 base pairs, and which presents more than 90% homology with the “consensus” *femA* nucleotide sequence (CNS) of Fig. 3 and the oligonucleotide of Claim 1]Claim 9 wherein said oligonucleotides have more than 90% homology to SEQ ID NOS:1, and 45-53.

Appl. No. : PCT/BE98/00141
Date : September 28, 1998

11. (Amended) [Couple of] The oligonucleotides according to [any one of the Claims 7 to 10, wherein the oligonucleotides having between 15 and 45 base pairs, preferably between 17 and 25 base pairs, and which present more than 60, 70, 80 or 90% homology with the "consensus" *femA* nucleotide sequence (CNS) of Fig. 3 are] Claim 7 wherein said oligonucleotides are selected from the group consisting of [the following nucleotide sequences:

- ANAATGAANTTTACNAATTTNACNGCNANAGANTT
and more particularly TAATGAAGTTTACAAAATTT or
TAATGAAGTTTACNAAATTT
- ATGNCNNANAGNCATTTNACNCANA
and more particularly TGCCATATAGTCATTTACGC
- TAGTNGGNATNAANAANAANNATAANGANGTNATTGC
- GTNCCNGTNATGAAANTNTTNAANTANTTTTATTC
- AATGCNGGNNANGATTGG
- GNAANNGNAANACNAAAAAGTNNANAANAATGGNGTNAAAGT
and more particularly AAAAAGTTCAAAAATGG and
AAAAAGTACAAAATGG
- AAGANGANN TNCCNATNTTNGNTCATTNATGGANGATAC
- TATATNNANTTTGATGANTA
- AANGANATNGANAAANGNCCNGANAANAAAAA
and more particularly AAAGATATTGAAAAACGA,
AAAGATATTGAAAAGAGACC, AAAGATATCGAGAAAGAC and
AAAGACATCGACAAGCGT.
- ANCATGGNAANGAATTACCNAT
and more particularly GAACATGGTAATGAATTAC
- AATCCNTNTGAAGTNGTNTANTANGCNGGTGG
- AGNTATGCNNTNCAATGGNNNATGATTAANTATGC
- TTTANNGANGANGCNGAAGATGNNGGNGTNNTNAANTTNAAAAA
and more particularly TTTACTGAAGATGCTGAAGA
- GTTGGNGANTTNNNTNAAACC
and more particularly GTTGGTGACTTTATTAAACC
- ATGAAATTTACAGAGTTAA] SEQ ID NOS:18-44.

13. (Amended) A method of [Identification]identification and/or quantification [method] of a *Staphylococci* species, which may present resistance to antibiotics and which is present in a sample, said method comprising the steps of:

- [—] obtaining a nucleotide sequence from a *Staphylococci* species present in the sample,
- [—] amplifying said nucleotide sequence with the [couple of] oligonucleotides according to [any one of the Claims 7 to 11] Claim 7, and
- [—] identifying and/or [possibly] quantifying the specific *Staphylococci* species:

Appl. No. : PCT/BE98/00141
Date : September 28, 1998

[—] by reverse hybridization of the amplified nucleotide sequence with one or more oligonucleotide(s) [according to any one of the Claims 1 to 6]having a nucleotide sequence comprising about 15 to 350 base pairs of SEQ ID NO:1, [which is (are)] specific of said *Staphylococci* species [and is (are)]wherein said nucleotide sequence is immobilized on a solid support or
[—] by a comparative measure of the length of the amplified nucleotide sequence.

14. (Amended) [Diagnostic] A diagnostic device for the identification of *Staphylococci* species comprising: [the]an oligonucleotide having a nucleotide sequence comprising about 15 to 350 base pairs of SEQ ID NO:1, and/or the [couple of]two or more oligonucleotides according to [any one of the preceding Claims 1 to 11]Claim 7 [and possibly all the media necessary for the identification of an amplified sequence of said *Staphylococci* species through any one of the methods selected from the group consisting of in situ hybridization, hybridization on a solid support, in solution on dot blot, Northern blot, Southern blot, probe hybridization by the use of an isotopic or non-isotopic label, genetic amplification or a mixture thereof].

15. (Amended) An isolated or purified *femA* [genetic sequence which presents]polynucleotide more than 90% [homology with a]homologous to the nucleotide [or amino acid] sequence selected from the group consisting of [the sequence SEQ ID NO 40, SEQ ID NO 41, SEQ ID NO 42, SEQ ID NO 43, SEQ ID NO 44, SEQ ID NO 45, SEQ ID NO 46, SEQ ID NO 47, SEQ ID NO 48, SEQ ID NO 49, SEQ ID NO 50, SEQ ID NO 51, SEQ ID NO 52, SEQ ID NO 53 and SEQ ID NO 54]SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, and 16.

16. (Amended) [Genetic sequence] The isolated or purified *femA* polynucleotide according to Claim [14, being the nucleotide sequence SEQ ID NO 40]15, wherein said polynucleotide comprises SEQ ID NO:2.

17. (Amended) [Genetic sequence] The isolated or purified *femA* polynucleotide according to Claim [14, being the nucleotide sequence SEQ ID NO 41]15, wherein said polynucleotide comprises SEQ ID NO:4.

Appl. No. : PCT/BE98/00141
Date : September 28, 1998

18. (Amended) [Genetic sequence] The isolated or purified *femA* polynucleotide according to Claim [14, being the nucleotide sequence SEQ ID NO 42]15, wherein said polynucleotide comprises SEQ ID NO:6.

19. (Amended) [Genetic sequence] The isolated or purified *femA* polynucleotide according to Claim [14, being the nucleotide sequence SEQ ID NO 43]15, wherein said polynucleotide comprises SEQ ID NO:8.

20. (Amended) [Genetic sequence] The isolated or purified *femA* polynucleotide according to Claim [14, being the nucleotide sequence SEQ ID NO 44]15, wherein said polynucleotide comprises SEQ ID NO:10.

21. (Amended) [Genetic sequence] The isolated or purified *femA* polynucleotide according to Claim [14, being the nucleotide sequence SEQ ID NO 45]15, wherein said polynucleotide comprises SEQ ID NO:12.

22. (Amended) [Genetic sequence] The isolated or purified *femA* polynucleotide according to Claim [14, being the nucleotide sequence SEQ ID NO 46]15, wherein said polynucleotide comprises SEQ ID NO:14.

23. (Amended) [Genetic sequence] The isolated or purified *femA* polynucleotide according to Claim [14, being the nucleotide sequence SEQ ID NO 47]15, wherein said polynucleotide comprises SEQ ID NO:16.

Please add the following Claims:

31. The oligonucleotide of Claim 5 wherein said sequence comprises about 17 to 25 base pairs.

32. The oligonucleotides according to Claim 7 wherein said nucleotide sequence comprises about 17 to 25 base pairs.

33. The diagnostic device of Claim 14 further comprising all of the media necessary for the identification of an amplified sequence of said *Staphylococci* species through any one of the methods selected from the group consisting of: *in situ* hybridization, hybridization on a solid support, hybridization in solution, hybridization on a dot blot, Northern blot, Southern blot, probe hybridization by the use of an isotopic label, probe hybridization by the use of a non-isotopic label, genetic amplification and a mixture thereof.

Appl. No. : PCT/BE98/00141
Date : September 28, 1998

34. An isolated or purified *femA* polypeptide more than 90% homologous to the amino acid sequence selected from the group consisting of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, and 17.

35. The isolated or purified *femA* polypeptide according to Claim 34, wherein said polypeptide comprises SEQ ID NO:3.

36. The isolated or purified *femA* polypeptide according to Claim 34, wherein said polypeptide comprises SEQ ID NO:5.

37. The isolated or purified *femA* polypeptide according to Claim 34, wherein said polypeptide comprises SEQ ID NO:7.

38. The isolated or purified *femA* polypeptide according to Claim 34, wherein said polypeptide comprises SEQ ID NO:9.

39. The isolated or purified *femA* polypeptide according to Claim 34, wherein said polypeptide comprises SEQ ID NO:11.

40. The isolated or purified *femA* polypeptide according to Claim 34, wherein said polypeptide comprises SEQ ID NO:13.

41. The isolated or purified *femA* polypeptide according to Claim 34, wherein said polypeptide comprises SEQ ID NO:15.

42. The isolated or purified *femA* polypeptide according to Claim 34, wherein said polypeptide comprises SEQ ID NO:17.

REMARKS

The specification has been amended to include a reference to the International Application No. of the present application, PCT/BE98/00141, filed September 28, 1998 and to assign Sequence Identification Numbers to the sequences disclosed in the Application.

Claims 3-4, 12, and 24-30, have been cancelled. Claims 31-42 have been added. The claims have been amended to more precisely claim the invention according to conventional practice before the United States Patent and Trademark Office.

As a result of the amendments made herein, Claims 1-2, 5-11, 13-23 and 31-42 are presented for examination. No new matter is being added herewith.

Appl. No. : PCT/BE98/00141
Date : September 28, 1998

Conclusion

Should there be any questions concerning this application, the Examiner is respectfully invited to contact the undersigned attorney at the telephone number appearing below

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 17 March 2000

By: Daniel Altman

Daniel E. Altman
Registration No. 34,115
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404

H:\DOCS\JAH\JAH-2180.DOC
030800

09/509234

1

5

10 GENETIC SEQUENCES, DIAGNOSTIC AND/OR QUANTIFICATION METHODS
AND DEVICES FOR THE IDENTIFICATION OF STAPHYLOCOCCI STRAINS

Field of the invention

The present invention refers to new genetic sequences, diagnostic and/or quantification methods and
15 devices using said sequences for the identification of various types of Staphylococci strains as well as the therapeutical aspects of said genetic sequences.

Background of the invention

20 Increasing incidence of nosocomial infections by multiresistant bacteria (even to antibiotics like vancomycin) is a world-wide concern. Methicillin-resistant coagulase-negative Staphylococci (MR-CNS) and *S. aureus* (MRSA) express a high level cross-resistance to all β -
25 lactam antibiotics (Ryffel et al. (1990), Refsahl et al. (1992)). They have an additional low-affinity penicillin-building protein, PBP2a (PBP2'), encoded by the *mecA* gene. The *mecA* determinant is found in all multiresistant staphylococcal species (Chackbart et al. (1989), Suzuki et
30 al. (1992), Vannuffel et al. (1995)) and is highly conserved among the different species (Ryffel et al. (1990)).

Several other chromosomal sites, in which transposon inactivation reduces the level of β -lactam resistance, have been identified in *S. aureus* (SA) (Hiramatsu (1992), Berger-Bächi et al. (1992), de Lancastre et al. (1994)). The appropriate functioning of these regulator genes rather than the quantity of PBP2a determines the minimal inhibitory concentration value and homogeneous expression of resistance of staphylococcal isolates (Ryffel et al. (1994), de Lancastre et al. (1994)).

The *femA-femB* operon, initially identified in *S. aureus*, is one of those genetic factors essential for methicillin resistance (Berger-Bächi et al. (1989)). It is involved in the formation of the characteristic pentaglycine side chain of the SA peptidoglycan (Stranden et al. (1997)). Unlike other regulatory genes, *femA* was shown to retain a strong conservation over time in clinical isolates of MRSA, hence confirming its key role in cell wall metabolism and methicillin resistance (Hurlimann-Dalel et al. (1992)). In contrast to *mecA*, *femA-femB* is present both in the genome of resistant and susceptible SA strains (Unal et al. (1992), Vannuffel et al. (1995)).

Often, identification of the *Staphylococci* is limited to a rapid screening test for *S. aureus*, and non-*S. aureus* isolates are simply reported as coagulase-negative *Staphylococci*. In fact, these bacteria isolates include a variety of species and many different strains (Kleeman et al. (1993)). There is little epidemiological information related to the acquisition and spread of these organisms. This is potentially due to the lack of an easy and accurate way to identify species and to provide clinically timely informations.

Several molecular assays designed for detecting *femA* in SA failed to amplify an homologous sequence in coagulase-negative *Staphylococci* (Kizaki et al. (1994), Vannuffel et al. (1995)). Nevertheless, low-
5 stringency heterologous hybridisation analysis suggested the presence of such a structurally related gene in *S. epidermidis* (SE) (Unal et al. (1992)).

These data were followed by complete identification and sequence analysis of the *femA* and *femB*
10 open reading frames in *S. epidermidis* (Alborn et al. (1996)). Intra- and interspecies relatedness of these genes and conservation of genomic organisation are therefore consistent with gene duplication of one of these genes in an ancestral organism and the possibility of *femA*
15 phylogenetic conservation in all staphylococcal species (Alborn et al. (1996)).

The complete genetic sequence of the *femA* gene de *S. epidermidis*, the protein encoded by the *femA* gene (*FemA*) and vectors and micro-organisms comprising
20 genes encoding the *FemA* protein are described in the US patent 5,587,307.

Aims of the invention

The present invention aims to provide new
25 genetic sequences, methods and devices for the improvement of the identification and/or the quantification of various types of *Staphylococci* strains through their *femA*-like determinants, which allow by a rapid screening their epidemiological study.

30 Another aim of the invention is to identify similar genetic sequences which may exist in known or not

known *Staphylococci* species or other gram-positive bacterial strains.

A last aim of the present invention is to provide new sequences encoding *femA* proteins of
5 *Staphylococci* species, their *femA* proteins, vector(s) comprising said nucleotide sequences and cell (s) transformed by said vector(s) for possible therapeutical applications.

10 Summary of the invention

The Inventors have identified new DNA and amino acid sequences from new strains of *Staphylococcus hominis*, *Staphylococcus saprophyticus* and *Staphylococcus haemolyticus*. Said new nucleotide sequences allow an
15 alignment of these new sequences with the *femA* gene from *Staphylococci* previously described (*S. aureus*, *S. epidermidis* and *S. saprophyticus*). By the alignment of more than 2 sequences, preferably more than 4 sequences, the Inventors have identified for the first time a consensus
20 *femA* sequence useful for molecular genotyping of different *Staphylococci* species which was not possible previously, when only few *femA* sequences of *Staphylococci* strains were known.

Therefore, a first aspect of the present
25 invention is related to the "consensus" nucleotide sequence as represented in the enclosed Figure 3. With said "consensus" nucleotide sequence, the Inventors were able to provide oligonucleotides (such as primers or probes) which can be used for the genetic amplification, the
30 identification and/or quantification of various *femA* sequences which are specific of known or unknown *Staphylococci* species.

The *femA* sequence is known to be involved with the biosynthesis of glycine-containing cross-bridges of the peptidoglycan and the peptidoglycan organisation is also known to be well conserved among various *Staphylococci* species and possibly among other gram-positive bacteria.

Therefore, it is also possible to use the new "consensus" *femA* sequence and said new oligonucleotides extrapolated from the alignment of the sequences presented in Figure 3, for the molecular genotyping of other *Staphylococci* species and possibly other gram-positive bacteria. It is also known that the *femA* sequence is similar to the *femB* sequence. Therefore, these oligonucleotides could also be used for the molecular genotyping of *femB* genes of different *Staphylococci* species or other gram-positive bacteria.

Another aspect of the present invention concerns the possible therapeutical uses of new *femA* nucleotide sequences isolated from the strains *S. hominis*, *S. saprophyticus*, *S. haemolyticus*, *S. lugdunensis*, *S. xylosus*, *S. capitis*, *S. schleiferi* and *S. sciuri* having a nucleotide or amino acid sequence which presents more than 85%, preferably more than 90% homology or 100% homology with the genetic sequences presented in the Figures 6 to 13, their complementary strand and functional variants thereof. Functional variants of said amino acid sequences are peptides which contain one or more modifications to the primary amino acids sequence and retain the activity of the complete and wild type *femA* molecule. Variants of the peptide are obtained by nucleotidic sequences which differ from the above-identified described sequences by a degeneration of their genetic code or are sequences which hybridise with said sequences or their complementary

strand, preferably under stringent conditions such as the ones described in the document Sambrook et al., §§ 9.47-9.51 in *Molecular Cloning : A Laboratory Manual*, Cold Spring Harbor, Laboratory Press, Cold Spring Harbor, New York (1989).

A further aspect of the present invention concerns the recombinant vector (i.e. constructions into which the sequence of the invention may be inserted for transport in different genetic environments and for expression in a host cell, such as a phagemide, a virus, a plasmid, a cationic vesicle, a liposome, etc.) comprising said nucleotide sequences and their complementary strands, or the corresponding RNA sequences, possibly linked to one or more regulatory sequences or markers (resistance to antibiotics, enzyme coding sequences, ...) active into a cell.

Similarly, the nucleic acid sequence according to the invention may be obtained by synthetic methodology well known by the person skilled in the art, such as the one described by Brown et al. ("Method of Enzymology", Acad. Press, New-York, No. 68 pp. 109-151 (1979)) or by conventional DNA synthesising apparatus such as the applied biosystem model 380A or 380B DNA synthesiser.

Other aspects of the present invention concern the recombinant host (prokaryotic) cell transformed by said vector and the purified (possibly recombinant) proteins or peptides encoded by said nucleic acid sequences, possibly linked to a carrier molecule such as BSA and obtained by said cells. Said recombinant proteins or peptides could be obtained by genetic engineering or could be obtained by synthesis (see US patent 5,587,307

incorporated herein by reference) and may comprise residues enhancing their stability (resistance to hydrolysis by proteases, etc.) such as the one described by Nachman et al. (Regul. Pept. Vol. 57, pp. 359-370 (1995)).

5 A preferred vector for expression in a *E. coli* host cell is derived from the *E. coli* plasmid pET-11A available from Novagen Inc. (Catalogue No. 69436-A). The transformation technique used with the above-identified vector has been described in the US Patent 5587307.

10 A further aspect of the present invention concerns the inhibitor (used to possibly treat (with addition of antibiotics) antibiotics resistance bacteria) directed against said proteins, peptides or nucleic acid molecules. Advantageously, said inhibitor is a antibody,
15 preferably a monoclonal antibody, or an antisense nucleotide molecule, such as a ribozyme, which could be present in a vector in order to block the expression of said *femA* nucleotide sequences.

A last aspect of the present invention
20 concerns the pharmaceutical composition, preferably a vaccine, against *Staphylococci* infections in an animal, including a human, comprising a pharmaceutically acceptable carrier and a sufficient amount of an active compound selected from the group consisting of said nucleic acid
25 molecules, vectors, recombinant host cells transformed by said vector(s), inhibitors (directed against said proteins, peptides or nucleic acid molecules) and a mixture thereof.

Another aspect of the present invention concerns oligonucleotides which are (DNA) sequences having
30 between 15 and 350 base pairs, preferably between 17 and 250 base pairs (such as primers or probes) obtained from the consensus sequence of Figure 3 or its complementary

strand. Preferably, said oligonucleotides are primers having between 15 and 45 base pairs, more preferably between 17 and 25 base pairs.

According to a first embodiment of the present invention, said oligonucleotide is a primer having between 15 and 45 base pairs, which presents more than 60%, advantageously more than 70%, preferably more than 80%, more specifically more than 90% homology with (fragments of) the "consensus" *femA* nucleotide sequence (CNS) identified in the Figure 3. :

Therefore, the oligonucleotides according to the invention are new sequences or preferred fragments of known sequences of *S. aureus*, *S. epidermidis* or *S. simulans* but not the complete wild type known *femA* nucleotide sequence.

Preferably, the oligonucleotide according to the invention is selected from the group consisting of the following nucleotide sequences :

- ANAATGAANTTTACNAATTTNACNGCNANAGANTT
- 20 and more particularly *femS1* TAATGAAGTTTACAAAATTT or *femS2* TAATGAAGTTTACNAAATTT
- ATGNCNNANAGNCATTTNACNCANA
- and more particularly *femU1* ("universal" sequence sense of the multiplex PCR): TGCCATATAGTCATTTACGC
- 25 - TAGTNGGNATNAANAANAANNATAANGANGTNATTGC
- GTNCCNGTNATGAAANTNTTNAANTANTTTTATTC
- AATGCGNGGNNANGATTGG
- GNAANNGNAANACNAAAAAGTNNANAANAATGGNGTNAAAGT
- and more particularly *fsq1S* (et 1AS) :
- 30 AAAAAGTTCAAAAAATGG and *fsq2S* (and 2AS) :
- AAAAAGTACAAAAATGG
- AAGANGANNTNCCNATNTTNGNTCATTNATGGANGATAC

- TATATNNANTTTGATGANTA
- AANGANATNGANAAANGNCCNGANAANAAAAA
- and more particularly *fsq3S* (and 3AS) :
- AAAGATATTGAAAAACGA, *fsq4S* (and 4AS) :
- 5 AAAGATATTGAAAAGAGACC, *fsq5S* (and 5AS) :
- AAAGATATCGAGAAAGAC and *fsq6S* (and 6AS) :
- AAAGACATCGACAAGCGT.
- ANCATGGNAANGAATTACCNAT
- and more particularly *fem1* (primer for the production
- 10 of a probe and of marked amplicons for reverse
- hybridisation experiment) : GAACATGGTAATGAATTAC
- AATCCNTNTGAAGTNGTNTANTANGCNGGTGG
- AGNTATGCNNTNCAATGGNNNATGATTAANTATGC
- TTTANNGANGANGCNGAAGATGNNGGNGTNNNTNAANTTNAAAAA
- 15 and more particularly *fem3bio* (primer for the
- production of a probe and of marked amplicons for
- reverse hybridisation experiment) :
- TTTACTGAAGATGCTGAAGA
- GTTGGNGANTTNNTNAAACC
- 20 and more particularly *fem2* (primer for the production
- of a probe and of marked amplicons for reverse
- hybridisation experiment) : GTTGGTGACTTTATTAAACC
- ATGAAATTTACAGAGTTAA (= *femAS1*)

25 Said primer(s) will be designated hereafter
as "universal primer(s)".

A further aspect of the present invention
concerns the oligonucleotide being either a primer or a
probe as above-described, having between 15 and 350 base
30 pairs, preferably between 17 and 250 base pairs, or a
primer having between 15 and 45 base pairs, more preferably
between 17 and 25 base pairs, which will be designated

hereafter as "specific primer(s)", having a nucleotide sequence which presents less than 50%, advantageously less than 40%, preferably less than 30%, more specifically less than 20% homology with (fragments of) the "consensus" *femA* nucleotide sequence (CNS) identified in the Figure 3 and with another *femA* nucleotide sequence specific for other *Staphylococci* strains.

Advantageously, said "specific primer" is selected from the group consisting of the following nucleotide sequences :

- ACAGCAGATGACATCATT
- TAATGAAAGAAATGTGCTTA
- ACACAACCTTCAATTAGAAC
- AGTATTAGCAAATGCGG
- 15 - ATGCATATTTTCCGTAA
- CAGCAGATGACATCATT
- CATCTAAAGATATATTAAATGGA
- AGTATTAGCAAATGCGGGTCAC
- CAACACAACCTTCAATTAGAA

20

The oligonucleotides according to the invention are selected according to their physiochemical properties in order to avoid cross-hybridisation between themselves. Said primers are not complementary to each other and they contain a similar percentage of bases GC.

25

Said oligonucleotides are used in an identification and/or quantification method of one or more *Staphylococcus* species and possibly other gram-positive bacteria.

30

Therefore, another aspect of the present invention is related to an identification and/or

quantification method of a *Staphylococci* species which may present resistance to one or more antibiotic(s), and is possibly combined with a method for the identification of a resistance to antibiotics, especially β -lactam antibiotics,
5 (for instance through the identification of a variant of the *mecA* gene as described by Vannuffel et al. (1998)).

The method for the detection, the identification and/or the quantification of a bacteria, preferably a staphylococcal species, comprises the steps
10 of :

- obtaining a nucleotide sequence from said bacteria present in a sample, preferably a biological body sample obtained from a patient such as blood, serum, dialyse liquid or cerebrospinal liquid, or from any other
15 bacteriological growth medium,
- possibly purifying said nucleotide sequence from possible contaminants,
- possibly amplifying by known genetic amplification techniques said nucleotide sequence with one or more
20 universal oligonucleotide(s) (universal primer(s)) according to the invention, and
- identifying the specific gram-positive bacteria species, preferably the specific *Staphylococci* species :
 - by a comparative measure of the length of the
25 (possibly amplified) nucleotide sequence or
 - by reverse hybridisation of the (possibly amplified) nucleotide sequence with one or more specific oligonucleotide(s) (specific probe(s) or primer(s)) according to the invention which are
30 specific of said bacteria, said oligonucleotide(s) being preferably immobilised on a solid support.

The comparative measure of the length of a possibly amplified nucleotide sequences can be performed by the analysis of their migration (compared with a known ladder) upon an electrophoresis gel.

5 Preferably, the genetic amplification technique is selected from the group consisting of PCR (US patent 4,965,188), LCR (Landgren et al., *Sciences*, 241, pp. 1077-1080 (1988)), NASBA (Kievits et al., *J. Virol. Methods*, 35, pp. 273-286 (1991)), CPR (patent WO95/14106)
10 or ICR.

The specific detection of the possibly amplified nucleotide sequences can be obtained by the person skilled in the art by using known specific gel electrophoresis techniques, in situ hybridisation,
15 hybridisation on solid support, in solution, on dot blot, by Northern blot or Southern blot hybridisation, etc.

Advantageously, the probes which are specific of the bacteria are immobilised on a solid support according to the method described in the international
20 patent application WO98/11253 incorporated herein by reference.

Said specific oligonucleotides (probes or "elongated" primers) have a length comprised between 50 and 350 base pairs, preferably between 120 and 250 base pairs,
25 and are fixed to the solid support by a terminal 5' phosphate upon an amine function of the solid support by carbodiimide reaction (as described in the document WO98/11253 incorporated herein by reference).

The solid support can be selected from the
30 group consisting of cellulose or nylon filters, plastic supports such as 96-well microtiter plates, microbeads,

preferably magnetic microbeads, or any other support suitable for the fixation of a nucleotide sequence.

The method according to the invention can be advantageously combined with another specific detection
5 step of a possible resistance to antibiotics, especially β -lactam antibiotics (for instance through the identification by the above-described technique of variants of the *mecA* gene as described by Vannuffel et al. (1998)).

The present invention concerns also a
10 diagnostic and/or quantification device or kit for the identification and/or the quantification of a *Staphylococcus* species or other gram-positive bacteria, comprising the oligonucleotides according to the invention and possibly all the media necessary for the identification
15 of a (possibly amplified) nucleotide sequence of said bacteria through any one of the above-described methods.

Advantageously, the method and device according to the invention are adapted for the quantification of said *Staphylococci* strains by the use of
20 a "internal or external standard sequence", preferably the one described in the patent application WO98/11253 incorporated herein by reference.

Therefore, according to a first embodiment of the present invention, the nucleic acid sequence from a
25 *Staphylococcus* species, for instance *Staphylococcus aureus*, is amplified by a "universal primer" and by a "specific primer" which is specific for *S. aureus*. The identification of *S. aureus* will be obtained upon an agarose electrophoresis gel wherein the amplified nucleotide
30 sequence (shorter than the amplified nucleotide sequence of another *Staphylococci* species such as *S. epidermidis*) and identified by the use of a comparative ladder.

According to another embodiment of the present invention, a *Staphylococcus* species (such as *S. aureus*) is identified by reverse hybridisation of the amplified nucleotide sequence with a probe which is
5 specific of said bacteria and which is immobilised on a solid support such as filter.

The present invention will be described in details in the following non-limiting examples, in reference to the Figures described hereafter.

10

Short description of the drawings

15

The Figure 1 represents 5 partially overlapping fragments of the *femA* genes from *S. hominis*, *S. saprophyticus* and *S. haemolyticus* obtained by PCR amplification.

20

The Figure 2 represents the alignment of the nucleotide sequences of *femA* genes from *S. hominis*, *S. saprophyticus*, *S. aureus*, *S. epidermidis* and *S. haemolyticus*.

25

The Figure 3 represents the consensus sequence according to the invention.

The Figure 4 represents the result of differential diagnosis between different strains of *Staphylococci* by reverse hybridisation.

30

The Figure 5 represents amplification of CNS species under universal conditions.

Figures 6 to 13 represent the complete *femA* wild type genetic sequence of the strains *S. hominis*, *S. saprophyticus*, *S. haemolyticus*, *S. lugdunensis*, *S. xylosus*, *S. capitis*, *S. schleiferi* and *S. sciuri*.

Examples

Example 1 : Sequencing strategy

Fragments of the *femA* genes from *S. hominis* and *S. saprophyticus* have been obtained by PCR amplification, in low stringency annealing conditions. Primers used for amplification are matching the potentially conserved regions and have been designed according to sequences homologies between *S. aureus*, *S. saprophyticus* and *S. epidermidis femA* nucleotide sequences. For both *S. hominis* and *S. saprophyticus* species, 5 partially overlapping fragments have been synthesised allowing the sequencing of the entire *femA* genes (Fig. 1).

Example 2 : Identification of a consensus sequence

Alignment of the nucleotide sequences of *femA* genes from *S. hominis* and *S. saprophyticus* as well as with *femA* genes sequenced to date from *S. aureus* (GenBank accession number M23918), *S. epidermidis* (GenBank accession number U23713) and *S. haemolyticus* is presented in Fig. 3 and has allowed to propose a "consensus" *femA* nucleotide sequence (CNS) whose genomic organisation displays highly conserved regions flanked by variable ones. On this basis, interspecies phylogenetic variations could be exploited to design genotyping strategies for species-specific identification of *Staphylococci*. The "consensus" sequence is therefore a powerful molecular tool for specific diagnostic of staphylococcal infections.

Example 3 : Sequencing of other staphylococcal *femA* genes

The consensus sequence can be exploited for designing universal primers allowing the production, under permissive annealing conditions, of overlapping PCR

products whose sequencing will identify the entire *femA* sequence.

Example 4 : Differential diagnosis between *S. aureus*, *S. epidermidis*, *S. hominis* and *S. saprophyticus* by reverse hybridisation

The Inventors have set up a reverse hybridisation assay for rapid and combined identification of the most clinically relevant *Staphylococci* species, and their *mecA* status. Two sets of primers, chosen in a conserved domain of the consensus sequence (*bioU1-bioU3* and *fem1-fem3bio*), amplifying a 286 and bio-220 bp fragments, respectively) were synthesised. Species-specificity of *femA* amplicons was insured by the genomic variability between the conserved regions. *FemA* probes were immobilised on nylon strips. Hybridisation was performed with biotinylated *femA* PCR fragments from the strain of interest. The strategy was first assessed with ATCC strains (*S. aureus*, *S. epidermidis*, *S. hominis* and *S. saprophyticus*) (Fig. 4). Specificity was identified by standard methods. Accuracy was 100% for species identification.

Example 5 : Differential diagnosis between staphylococcal species

This assay is able to identify any staphylococcal species if following requirements are fulfilled :

- primers *fem1*, *fem2* and *fem3bio* are universal for *Staphylococci*;
- there is a wide enough phylogenetic variation between any CNS species to promote a specific hybridisation.

The first requirement is fulfilled for, i.e., *S. haemolyticus*, *S. capitis*, *S. cohnii*, *S. xylosus*, *S. simulans*, *S. lugdunensis*, *S. schleiferi* and *S. warneri* strains (Fig. 5).

5

Example 6 : Multiplex amplification of femA and mecA genetic determinants for a molecular diagnosis of a specific staphylococcal infection

A total of 48 patients treated in 4
10 contiguous intensive cares units were included in the study. Endotracheal aspirates (ETA) were collected from the patients and submitted to the multiplex PCR analysis according to the technique described by Vannuffel et al. (1995). Clinical specimens were homogenised in 5 ml of TE
15 buffer (20 mM TRIS HCl, pH 8.0, 10 mM EDTA) containing 2% (w/v) SDS.

The homogenate (1.5 ml) was then centrifuged for 5 minutes at 7500 xg. The cellular pellet was washed once with TE buffer lysed in the presence of 1% (v/v)
20 Triton X-100 and 50 µg of lysostaphin (Sigma) and incubated for 15 minutes at 37 °C. Lysis was completed by adding 100 µg of proteinase K (Boehringer). The lysate was incubated for another 5 minutes at 55 °C and 5 minutes at 95 °C, and centrifuged at 4000 xg for 5 minutes.

25 In order to purify bacterial DNA, 200 µl of supernatant were then filtered on a Macherey-Nagel Nucleospin C+T® column and eluted with 200 µl sterile H₂O. Two different amounts of DNA suspension (2 µl and 200 µl) were submitted to multiplex PCR amplification with the
30 primers 5'-TGGCTATCGTGTCAACAATCG-3' and 5'-

CTGGAACCTTGTTGAGCAGAG-3' for *mecA* and the above-described primers for *femA*, yielding different fragments.

femA and *mecA* signals were found in specimens containing either susceptible *S. aureus* (n = 10) and
5 methycillin-resistant coagulase-negative *Staphylococci* (n = 6) respectively. On the other hand, no signal was obtained from ETA gram-negative bacteria (n = 5) as well as MS-CNS (n = 6) and from 5 ETA containing normal pharyngeal flora.

10 This multiplex, PCR strategy for detecting *Staphylococci* in ETA was completed in less than 6 hours either on the day of the samples' collection. This is an advantage with respect to the time required to conventional identification and susceptibility tests (48 to 72 hours).

15

Example 7 : Amplification, cloning and sequencing of other *femA* genes

Two primers were selected among the conserved parts of the consensus sequence for the amplification of
20 the *femA* gene.

These primers are *femS1*, *femS2* and *femAS1* (anti-sense primer). ADN from strains of *Staphylococcus hominis*, *saprophyticus*, *haemolyticus*, *lugdunensis*, *schleiferi*, *sciuri*, *xylosus*, *simulans*, *capitis*, *gallinarum*,
25 *cohnii* and *warneri* were amplified from said primers and amplification fragments were cloned in the vector pCR®-XLTOPO and introduced by electroporation in *E. coli* cells TOP10 (TOPO XL PCR Cloning Kit®, Invitrogen, Carlsbad, CA).

Amplified fragments of strain *S. lugdunensis*,
30 *schleiferi*, *sciuri*, *xylosus*, and *capitis* were sequenced by Taq Dye Deoxy Terminator Cycle® sequencing on a ABI 277 DNA

sequencer® (PE Applied Biosystems, Foster City, CA) by the following primers :

femS1 or *femS2* or *femAS1*

fsq1S and *fsq1AS*

5 *fsq2S* and *fsq2AS*


fsq3S and *fsq3AS*

fsq4S and *fsq4AS*

fsq5S and *fsq5AS*

fsq6S and *fsq6AS*

10



REFERENCES

1. Alborn W.E. Jr et al., Gene 180 : 177-81 (1996)
2. Berger-Bächli B. et al, Mol Gen Genet 219 : 263-9 (1989)
3. Berger-Bächli B. et al., Antimicrob. Agents Chemother.
5 36 : 1367-73 (1992)
4. Chackbart et al., Antimicrobial Agent Chemotherapy 33 :
991-999 (1989)
5. de Lancastre H. et al., Antimicrob. Agents Chemother.
38 : 2590-8 (1994)
- 10 6. Hiramatsu K. et al., FEBS, Letters 298 : 133-6 (1992)
7. Hurlimann-Dalel R.L. et al., Antimicrob. Agents
Chemother. 36 : 6+17-21 (1992)
8. Kizaki M. et al., J. Hosp. Infect. 28 : 287-95 (1994)
9. Kleeman K.T. et al., J. Clin. Microbiol. 31 : 1318-1321
15 (1993)
10. Refshal K. et al., J. Hosp. Infect. 22(1) : 19-31
(1992)
11. Ryffel C. et al., Gene 94 : 137-8 (1990)
12. Ryffel C. et al., Antimicrob. Agents Chemother. 38 :
20 724-8 (1994)
13. Rupp M.E. et al., Clin. Infectious Diseases 19 : 231-
245 (1994)
14. Stranden A.L. et al., J. Bacteriol. 179 : 9-16 (1997)
15. Suzuki E. et al., Antimicrob. Agents Chemother. 36 :
25 429-34 (1992)
16. Unal S. et al., J. Clin. Microb. 30 : 1685-1691 (1992)
17. Vannuffel P. et al., J. Clin. Microb. 33 : 2864-2867
(1995)
18. Vannuffel . et al., J. Clin. Microb. 36 : 2366-2368
30 (1998)

CLAIMS

5 1. Oligonucleotide for the specific identification of *Staphylococci* species having a nucleotide sequence comprising between 15 and 350 base pairs, preferably between 17 and 250 base pairs, and which presents less than 50% homology with the "consensus" *femA* nucleotide sequence (CNS) of Fig. 3.

15 2. Oligonucleotide according to claim 1 for the specific identification of *Staphylococci* species having a nucleotide sequence comprising between 15 and 350 base pairs, preferably between 17 and 250 base pairs, and which presents less than 40% homology with the "consensus" *femA* nucleotide sequence (CNS) of Fig. 3.

20 3. Oligonucleotide according to claim 1 or 2 for the specific identification of *Staphylococci* species having a nucleotide sequence comprising between 15 and 350 base pairs, preferably between 17 and 250 base pairs, and which presents less than 30% homology with the "consensus" *femA* nucleotide sequence (CNS) of Fig. 3.

25 4. Oligonucleotide according to any of the claims 1 to 3 for the specific identification of *Staphylococci* species having a nucleotide sequence comprising between 15 and 350 base pairs, preferably between 17 and 250 base pairs, and which presents less than 20% homology with the "consensus" *femA* nucleotide sequence (CNS) of Fig. 3.

30 5. Oligonucleotide according to claim 1, being a primer which nucleotide sequence has between 15 and 45 base pairs, preferably between 17 and 25 base pairs.

35 6. Oligonucleotide according to claim 5, which is selected from the group consisting of the following nucleotide sequences :

AMENDED SHEET

9. Couple of oligonucleotides according to claim 7 or 8 for the specific amplification of *Staphylococci* species, consisting of two different

RCV. VON: EPA MUENCHEN 06 : 19-1-0 : 14:02 : +32 2 4263760- +49 89 23994465: # 7

5

10

20

—

30

RCV:YON:EPÄ MOENHEN 06 : 19-1-0 : 14:02 : +32 2 42637604 : +49 89 23994465: # 8

- GNAANNNGNAANACNAAAAAAGTNNANAANAATGGNGTNAAAGT
and more particularly AAAAAAGTTCAAAAAATGG and
AAAAAGTACAAAAAATGG
- AAGANGANNTNCCNATNTTNGNTCATTNATGGANGATAC
- 5 - TATATNNANTTTGATGANTA
- AANGANATNGANAAANGNCCNGANAANAAAAA
and more particularly AAAGATATTGAAAAACGA,
AAAGATATTGAAAAGAGACC, AAAGATATCGAGAAAGAC and
AAAGACATCGACAAGCGT.
- 10 - ANCATGGNAANGAATTACCNAT
and more particularly GAACATGGTAATGAATTAC
- AATCCNTNTGAAGTNGTNTANTANGCNGGTGG
- AGNTATGCNNTNCAATGGNNNATGATTAANTATGC
- TTTANNGANGANGCNGAAGATGNNGGNGTNTNAANTTNAAAAA
- 15 and more particularly TTTACTGAAGATGCTGAAGA
- GTTGGNGANTTNTNAAACC
and more particularly GTTGGTGACTTTATTAACC
- ATGAAATTTACAGAGTTAA
- 20 12. Oligonucleotide having between 15 and 45
base pairs, preferably between 17 and 25 base pairs,
which is selected from the group consisting of the
following nucleotide sequences:
- ANAATGAANTTTACNAATTTNACNGCNANAGANTT
and more particularly TAATGAAGTTTACAAAATTT or
- 25 TAATGAAGTTTACNAAATTT
- ATGNCNNANAGNCATTTNACNCANA
and more particularly TGCCATATAGTCATTTACGC
- TAGTNGGNATNAANAANAANNATAANGANGTNATTGC
- GTNCCNGTNATGAAANTNTTNAANTANTTTTATTC
- 30 - AATGCNCGNNANGATTGG

AMENDED SHEET

- GNAANNGNAANACNAAAAAAGTNNANAANAATGGNGTNAAAGT
and more particularly AAAAAAGTTCAAAAAATGG and
AAAAAGTACAAAAAATGG
- AAGANGANNTNCCNATNTTNGNTCATTNATGGANGATAC
- 5 - TATATNNANTTTGATGANTA
- AANGANATNGANAAANGNCCNGANAANAANAAAA
and more particularly AAAGATATTGAAAAACGA,
AAAGATATTGAAAAGAGACC, AAAGATATCGAGAAAGAC and
AAAGACATCGACAAGCGT.
- 10 - ANCATGGNAANGAATTACCNAT
- AATCCNTNTGAAGTNGTNTANTANGCNGGTGG
- AGNTATGCNNTNCAATGGNNNATGATTAANTATGC
- TTTANNGANGANGCNGAAGATGNNGGNGTNNNTNAANTTNAAAAA
and more particularly TTTACTGAAGATGCTGAAGA
- 15 - GTTGGNGANTTNNTNAAACC
- and more particularly GTTGGTGACTTTATTAAACC
- ATGAAATTTACAGAGTTAA

13. Identification and/or quantification
method of a *Staphylococci* species, which may present
20 resistance to antibiotics and which is present in a
sample, said method comprising the steps of :

- obtaining a nucleotide sequence from a *Staphylococci*
species present in the sample,
- amplifying said nucleotide sequence with the couple of
25 oligonucleotides according to any one of the claims 7 to
11, and
- identifying and possibly quantifying the specific
Staphylococci species :
- 30 - by reverse hybridisation of the amplified
nucleotide sequence with one or more
oligonucleotide(s) according to any one of the
claims 1 to 6 which is (are) specific of said
Staphylococci species and is (are) immobilised on a
solid support or

AMENDED SHEET

- by a comparative measure of the length of the amplified nucleotide sequence.

14. Diagnostic device for the identification of *Staphylococci* species comprising the oligonucleotide or
 5 the couple of oligonucleotides according to any one of the preceding claims 1 to 11 and possibly all the media necessary for the identification of an amplified sequence of said *Staphylococci* species through any one of the methods selected from the group consisting of in situ
 10 hybridisation, hybridisation on a solid support, in solution on dot blot, Northern blot, Southern blot, probe hybridisation by the use of an isotopic or non-isotopic label, genetic amplification or a mixture thereof.

15 15. *femA* genetic sequence which presents more than 90% homology with a nucleotide or amino acid sequence selected from the group consisting of the sequence SEQ ID NO 40, SEQ ID NO 41, SEQ ID NO 42, SEQ ID NO 43, SEQ ID NO 44, SEQ ID NO 45, SEQ ID NO 46, SEQ ID NO 47, SEQ ID NO 48, SEQ ID NO 49, SEQ ID NO 50, SEQ ID NO 51, SEQ ID NO 52, SEQ
 20 ID NO 53 and SEQ ID NO 54.

16. Genetic sequence according to claim 14, being the nucleotide sequence SEQ ID NO 40.

17. Genetic sequence according to claim 14, being the amino acid sequence SEQ ID NO 41.

25 18. Genetic sequence according to claim 14, being the nucleotide sequence SEQ ID NO 42.

19. Genetic sequence according to claim 14, being the amino acid sequence SEQ ID NO 43.

30 20. Genetic sequence according to claim 14, being the nucleotide sequence SEQ ID NO 44.

21. Genetic sequence according to claim 14, being the amino acid sequence SEQ ID NO 45.

22. Genetic sequence according to claim 14, being the nucleotide sequence SEQ ID NO 46.

AMENDED SHEET

23. Genetic sequence according to claim 14,
being the amino acid sequence SEQ ID NO 47.

24. Genetic sequence according to claim 14,
being the nucleotide sequence SEQ ID NO 48.

5 25. Genetic sequence according to claim 14,
being the amino acid sequence SEQ ID NO 49.

26. Genetic sequence according to claim 14,
being the nucleotide sequence SEQ ID NO 50.

10 27. Genetic sequence according to claim 14,
being the amino acid sequence SEQ ID NO 51.


28. Genetic sequence according to claim 14,
being the nucleotide sequence SEQ ID NO 52.

29. Genetic sequence according to claim 14,
being the amino acid sequence SEQ ID NO 53.

15 30. Genetic sequence according to claim 14,
being the nucleotide sequence SEQ ID NO 54.

AMENDED SHEET

1/20

Oligonucleotides

femX1	TTCMAATCGCGGTCCAGT	213-230
femX2	CAAGAACATGGCAACGAATTACC	913-935
femX3	TGGGTAATTCGTTGCCATGTTCT	937-915
femX4	CCAAGCATCTTCAGCATCTTC	1133-1113
femX5	TTCTTTAACTGTAACTCTGTAAATTTCA	1309-1281
femX6	ACATATTTACTTAATTCGTTAAAGAA	290-265
femX7	CAGAAAAATGGTGTTAAAGTAAGATT	559-585
femX8	AAGAAATCTTACTT TCACACCATTTT	588-562
femX9	AACTCGAAAATAGAACTA	(-43)-(-26)

FIG. 1

FIG2a

S. haemolyticus	gag-t-----g-----a-----a-a-a-t-c-g-tg-caat-a-a-taag--c-at-t-t-----c-a--a-tgact-aa
S. hominis	aggagttata gag-t-----g-----a-----a-a-a-t-c-gat-t--t-aaaa--c-at-t-c-----t-a--g-tgact-aa
S. aureus	aatagagta atg-t-----g-----a-----a-a-a-t-a-g-tg-tgct-t--a-tagc--c-at-c-t-----c-g--a-ctgtt-gc
S. epidermidis	gggagttatg aag-t-----g-----g-----g-a-a-t-a-a-ta-tgac-t--t-ttgt--a-at-c-t-----t-a--a-tggaa-gt
S. saprophyticus	aggagttatg aaa-a-----g-----g-----g-a-a-t-a-a-g-g-cg-tgca-t--g-taaa--c-ga-t-t-----t-g--a-tgggt-ga
CONSENSUS	---A-NATGA A-TTTAC-AA TTTAC-GC- A-AGA-TT- G----T-TAC-GA-----ATG-C-A-AG-C ATTTAC-CA-A-----G--100
S. haemolyticus	a-c-t-t-ga-g-ag-----aa-taaaca--aa-t-ct-----t-t-t-a-a-t-a-g-----t-g-----t-----a--c-ca-gt-g--a-a-a-a-
S. hominis	tg-gaaaact--aa-t-ct-----t-t-t-a-a-t-a-g-----t-g-----t-----a--c-ca-gt-g--a-a-a-a-
S. aureus	tg-agggttat--aa-a-tt-----t-g-a-a-a-a-c-t-a-c-g-----c-g-----c-----a--t-ct-ac-t--t-t-t-a-
S. epidermidis	tg-agggtacc--gt-a-tt-----t-a-t-t-t-g-----t-g-----t-----a--c-g-----c-----a--t-ct-ac-t--t-t-t-a-
S. saprophyticus	ag-aagtaca--aa-a-cc-----a-a-t-t--t-g-t-t-g-----t-a-a-----a--a--tt-ac-t--a-tt-ac-t--a-tt-t-
CONSENSUS	-A-TA-GA--T-AA--TTGC--GA-C-CA--TAGT-GG-AT-AA-AA-AA--ATAA-GA-G-T-ATGC-GC-TG--T-T-AC-GC-GT-C200
S. haemolyticus	-a-c-----t-t-t-t-g--c-----t-cc-a-a--a-t-a-a-t-----a-g-t--tag--g--t-t-t-c-tt-----t--g-aaca--
S. hominis	-a-t-t-t-a--t-----a-tc-t-t--t-a-c-t--t-a-g-a--caa--a--c-t-c-tt-----c--a-aagt--
S. aureus	-g-g-c-g--t-----a-tc-c--t-a-g-t--a-a-g-a--tca--a--c-a-c-tt-----t--a-atca--
S. epidermidis	-a-a-t-a--t-----c-tc-c--t-a-a-a--a-a-t--taa--g--t-a-t-tt-----t--a-gagt--
S. saprophyticus	-t-c-c-g--t-----c-ta-a--t-a-c-a--t-t-g-a--taa--a--c-a-t-ac-----c--a-agca--
CONSENSUS	C-GT-ATGAA A-T-TT-AA-TA-TTTTATT C-AA-G-GG-CC-GT-AT-GATT-T-A-A-A-AGA-CT-GT-CA-T--TTCTTAA-G A-TT---AA300
S. haemolyticus	g--t-a--c-gc-taa-t gtc-----tg--tcgag-t-c--t-tt-ac-a-----t-t-t-aa-taca-gt--t-t-ta-t
S. hominis	a--t-a--c-ac-aca-t gtt-----tg--acgta-a-c--t-tt-gc-t-----t-t-ta-taca-ga--t-t-ga-t
S. aureus	a--g-t--a-ac-tcg-t gtc-----cc--acata-c-t--a-tt-ac-a-----cttg-----t-t-c-ga-taca-gt--t-t-ta-t
S. epidermidis	a--g-a--a-at-taa-t gtt-----tt--aagat-t-c--a-cc-tc-a-----t-tta-----g-a-a-a-aact-ga--a-tc-t
S. saprophyticus	a--g-a--a-ac-taa-g cct-----tt--acgag-a-t--t-tc-tg-t-----tcgt-----t-t-t-ag-atta-ca--g-g-tc-c
CONSENSUS	-TAT-T-AAA-A-A---T--TATA-T-----T-GA-CC-TA-T--C-TATCAATA-----ATCAT GA-GG-GA--T----G-AA TGC-GG-A-400
S. haemolyticus	-----t-c--t--a-ga-gaagcatc-c--a-t-g-a--tgaa-c--tact-aa-t-----t-ga-taaa-----cc-a-at-t--t-tt-g
S. hominis	-----t-c--c--a-aa-gaaacaat-a--a-a-c-a--cgaa-g--taca-ca-a-----t-t-aa-atta-----tc-g-tc-t--a-tt-a
S. aureus	-----t-c--t--a-aa-gagtaact-a--a-t-g-a--tact-aa-a--ccat-aa-a-----t-tg-gcta-----tc-t-at-c--a-gt-g
S. epidermidis	-----a-t--t--g-at-agagagtt-a--a-a-a--cgaa-a--ccac-aa-a-----t-tg-atta-----cc-a-at-t--t-tc-a
S. saprophyticus	-----a-t--t--a-aa-gaaacaac-c--t-a-a-g--tgaa-t--t-ta-ct-c-----c-aa-actt-----aa-a-tc-t--t-tt-g
CONSENSUS	GATTGG-T-T-T-GAT-A-T-----T-GG-T-T-A-C-A-----GG-TT-----A-GG-TTTGA-CC--T----CAAT TC-GT-TA-500
S. haemolyticus	-----aaaaa t-----cat-t-a-a-ta-at-a-tgga-----a-tc-a-c-t-ac-t--t-t-----t-c-a-a-----taag--
S. hominis	-----aagga t-----ctg-t-a-a-tg-at-a-tgga-----a-tt-a-c-a-a-a--t-t-----c-c-a-a-----t-t-----aaga--
S. aureus	-----aaga t-----cag-a-g-t-ca-ca-t-aaat-----g-ac-t-a-a-aa-a--c-g-----t-a-a-g-----t-t-----aaga--
S. epidermidis	-----gcaa c-----gtg-t-a-t-tg-tt-a-aaac-----g-tt-a-a-gc-t--t-t-----t-a-g-a-----a-t-----ccgc--
S. saprophyticus	-----gctgg a-----ctg-t-a-a-cg-ac-t-tggt-----a-tt-a-c-t-ac-a--t-t-----ac-g-a-----t-g-----aaga--
CONSENSUS	ATTTA-----AAAA---C--A-GA--T--T-AA-----AT GGAT-G--T--G-AA--G-A-A-AC-AAAA AGT--A-AA-AATGG-GT-A AAGT---TT600
S. haemolyticus	ct-atcag--a-a-ac-t--a-c-cc--t-----t--a-----aa--c-aa-g--a-aa-ccaa--a-a-a-t--tagt--c--t-t-tc-c
S. hominis	tc-tacta--a-at-a--t-t-t-ca-a-----t--a-----at-a-ga-t--a-aa-ttct--a-a-g--tagt--t--c-t-tc-a
S. aureus	tt-atctg--a-ac-a--t-t-ta-g-----t--g-----gt-a-at-a--a-ct-tgct--c-t-t--caaa-t--c-c-tc-c
S. epidermidis	tt-atctg--a-gt-a--t-a-ta-g-----t--g-----ct-t-aa-t--a-at-tgca--a-a-a--tagt--t--t-c-c-tc-a
S. saprophyticus	tt-aggtg--t-gt-g--a-a-cc--c-----c--a-----tt--t-aa-a--g-at-tgac--a-a-t--cgat--t--t-t-ta-g
CONSENSUS	--T-----AA GA-GA--T-C C-AT-TT-C TCATT-ATG GA-GATAC--C-GA-C-AA-G-TT---GAT-G-GA-G A----TT-TA-TA-AA--G-700

FIG. 2b

S. haemolyticus	-atagac---tc-----tca c-gc-t-a--ac-a-a-t--ta-g--g-c-a-cga--t-ac-aaat--ac-tg-aact t-a-a-----	800
S. hominis	-ttgatc---tt-----tag a-at-a-a--tc-c-a--aa-a--a-c-tga--c-te-tga--ac-tc-gaca t-a-a-----	
S. aureus	-taaat---ac-----ccg t-gt-a-a--tt-a-g--ca-c--a-t-a-taa--c-aa-cga--gc-tg-tatt t-a-a-----	
S. epidermidis	-tcaaac---at-----ccg t-tt-a-a--ac-a-c--ta-c--g-t-a-agg--c-aa-taat--aa-aa-tgg t-a-a-----	
S. saprophyticus	-taagat---at-----tcg t-gc-t-a--at-a-t--gg-t--a-a-a-a--t-a-a-a--t-a-gggt--ac-cg-agta t-a-g-----	
CONSENSUS	T-----ATT -AAAGA---GT-T-GT-CC--T-GC-T ATAT--A-TT TGATGA-TA--T-----GAA--T-A-----GA -G-A-----T-A-TAAAG	
S. haemolyticus	801	
S. hominis	-tgttt-t--tt-a-a--tt-t-a--c-a-a--c-t-----g--atatt--t-aaaagaa--tc-tg--a-a--t-agat--c-tc-a-----	
S. aureus	-ctta-c--tt-a-a--tt-t-a--c-a-a--t-c-----a--acaa--t-aaaata--tt-ag--c-g--t-aaaa--a--tg-g-----	
S. epidermidis	-ttta-t--gt-a-g--c-t-t-a--c-t-t--a--g-t-----a--acat--c-gcgagat--ct-ac--c-a--c-tgat--a--tg-g-----	
S. saprophyticus	-tata-t--tt-a-a--c-c-t-g--c-t-a--g-t-----a--acat--c-aaagaa--tt-ag--c-a--c-cgat--a--tc-g-----	
CONSENSUS	A-----AA-AGC--T-AA--GA-AT-GA-A-AA-G-CC-GA -AA-AAAA--GC-----AA-A-A-----AA -T-AA-A--CAA-T-----G C-AA--A-CA 900	
S. haemolyticus	901	
S. hominis	---at-ag-c--g-ct-aaa aat-ac-gc cg-a-----t--t-----a--t-a--a-gt-t--c-t-t-t-----a-t-----t-t-t-t-t	
S. aureus	---aa-tg-t--a-ca-cac aac-tc-tt ag-a-----t--c-----a--a-a--t--ga-t--c-t-t-t-----a-t-----t-a-t-t-t	
S. epidermidis	---ga-tg-a--a-gt-aac gtc-ac-ga ag-a-----t--t-----t--c-t--t-gt-t--c-t-t-c-----a-t-----t-t-t-t-t	
S. saprophyticus	---aa-ta-t--a-ct-aaa act-aa-ca ag-a-----c--t-----c--c-t--t-gc-t--t-a-a--t--g-t-----a-t--c-c	
CONSENSUS	AAA--T--A--GA-G--A---T--AA--T--CAATGG--AA-GAATTA--C-AT-TC-GC -G-T-CIT--T-AT-AATC C-T-TGAAGT -GT-TA-TA- 1000	
S. haemolyticus	1001	
S. hominis	-a-----a--t-t--aa-a-ata-a-t--t-a-c--t-----ta--t-----c-----aa-tg--t--ggt--t g-ta-a-c-	
S. aureus	-t-----a--g-a--aa-a-ata-a-c--c-t-a--t-----ag--t-----act-----t-----aa-tg--t--ggc--t g-cc-t-t-	
S. epidermidis	-t-----t--a-a--gc a-tcc-t-t--t-c-a--t-----ag--g-----gaa-----t-----at-aa--t--ggc--t g-cc-t-t-	
S. saprophyticus	-t-----a--t-a--cg t-acc-t--t-a-g--c-----gg--t-----aag-----c-----aa-tg--a--ggt--t a-tc-g-t-	
CONSENSUS	GC-GGTGG-A C-TC-AAT--T--G-CA--TT-GC-GG-A G-TATGC-T CAATGG---ATGATTAA-T ATGC--T--A--CAT---AT--A--G-TA-A 1100	
S. haemolyticus	1101	
S. hominis	---c-----ta---c---a-t---gt--a-a-c--t--tt-a--ca-t-a--t-----a--tca-----c-g-aa-t--g-t-----	
S. aureus	---t-----ga---t---c-t---ca--t-t-t--t--ca-t--tg-a-a--t-----a--tca-----a-tg-aa-t--a-t-----	
S. epidermidis	---c-----tg---t---a-a--ca--a-t-t--t--ct-t--ag-t-a--c-----a--taca-----t-aa-ta-t--a-t-----	
S. saprophyticus	---c-----ta---t---g-c---gt--a-t-t--t--ct-c--ag-t-g--t-----g--c-atg---c-tg-ta-a--a-c-----	
CONSENSUS	ATT-TATGG --TTAG-GGT -A-TTTA--G A-GA-CC-GA AGATG--GG- GT--T-AA-T T-AAAA-GG -T---ATGC- GA--T--T-G A-TA-GTTGG 1200	
S. haemolyticus	1201	
S. hominis	a--c--tg-g-----t--t--c--a--tt--g--ttcagt--aga--c--c-----ga--ta-aaa-ga tttaat--aa g-ggggaat--gacg-atatg	
S. aureus	t--t--cg-t-----t--a--t--a--aa--g--ttcacta--caa--c--t-----aa--ta-aaag-ga ttgaat--ag a-ggggaat--gtga-a---	
S. epidermidis	t--c--ta-t-----a--t--t--a--tg--t--cgcagca--ccg--c--t-----ag--ta-agac-ga atttt--gg a-ggggaatt--tcaa-ac---	
S. saprophyticus	t--c--ta-t-----t--t--a--aa--g--taacatt--gaa--c--t-----ac--aaga-at agattt--ag a-ggggaatt--tcta-tt---	
CONSENSUS	-GA-TT--T- AAACC-AT-A A-AA-CC--T -TA-----TATA---CA- T-AAAA--T -A-----TA--A-----A -A-----A -A-----A 1300	
S. haemolyticus	1301	
S. hominis	-----atga aattacag agttaac	
S. aureus	-----atga aattacag agttaacct	
S. epidermidis	-----atga aattacag agttaaca	
S. saprophyticus	gtagaatga aattacag agttaac	
CONSENSUS	-----ATGA AATTACAG AGTTAA---	

NNNNNNNN NNNAAATGA ANTTTACNAA TTTNACGCGN ANAGANTTNN GNNNTNTAC NGANNNTATG NCNNANAGNC ATTTNACNCA NANNNNNGNN
 NANTANGANN TNAANNTTGC NNANNNNNNN TAGTNGGNAT NAANAANAAN NATAANGANG TNATTGCGC NGNTNTNTN ACNGCGTNC
 CNGTNATGAA ANTNTTNAAN TANTTTTATT CNAANNNGG NCCNGTNATN GATTNTNANA ANNNAGANCT NGTNCANTNN TTTCTTTAANG ANTNNNNAA
 NTATNTNAAA NANNANNTN NNTTATANT NNNNTNGAN CCTANTNN CNTATCAATA NNNNAATCAT GANGGANGN TNNNGNNA TGCNGGNNAN
 GATTGGTNT TNGATNANT NNNNNNNTN GGNTNTNANC ANNNNGGNTT NNNNANGGN TTTGANCCNN TNNNCAAT NGNTNNCAN TCNGTNNNTAN
 ATTTANNNN NAAAANNNCN NANGANNTN TNAANNNTAT GGATNGNNTN NGNAANNNGNA ANACNAAAA AGTNANAAN AATGGGTNA AAGTNNNTT
 NNTNNNNAA GANGANNTC CNATNTTNG CCNTNGCNT ATATNNNTT TGATGANTAN NTNNNGAAN TNNNNGA NGNNANNNN NTNANTAAAG
 TNNNNNATT NAAAAGANN NGTNTNGTN CCNTNGCNT ATATNNNTT TGATGANTAN NTNNNGAAN TNNNNGA NGNNANNNN NTNANTAAAG
 ANNNNAANA AGCNTTNAAN GANATNGANA AANGNCCNGA NAANAANAAN GCNNNNAANA ANNNNNNA NNTNNAAN CAANTNNNG CNAANNANCA
 AAANTNNAN GANGNNANN NNTNNAAN NNATCATG NNAATATAC AANGAATATC CNATNTCNGC NGNTNCTTN NTNATNAATC CNTNTGAAGT NGTNTANTAN
 GCNGGTGGA CNTCNAATNN NTNNGNCAN TTNGCNGGNA GNTATGCNT NCAATGNNN ATGATTAAAT ATGCNNTNNA NCATNNNATN NANNGNTANA
 ATTTNTATGG NNTAGNGGT NANTTTANNG ANGANGCNGA AGATGNNNGN GTNNTNAANT TNAAAAANG NTNNNATGCN GANNTNTNG ANTANGTTGG
 NGANTTNTN AAACCNATNA ANAACCNNT NTANNNNNN TATANNNCAN TNAAAAANNT NNANNNNANN NNNNNNTANN NNNNNNNNA NNNNANNNN
 NNNNNATGA AATTACAG AGTTAANN

FIG.3 CONSENSUS SEQUENCE


220 bases	<i>S. aureus</i>	<i>S. epidermidis</i>	<i>S. hominis</i>
<i>S. aureus</i>	-	-	-
<i>S. epidermidis</i>	17.7	-	-
<i>S. hominis</i>	13.2	16.8	-
<i>S. saprophyticus</i>	17.3	18.6	16.8

Base % (non apparated) between the primers bioU1 and bioU3

FIG4a

FIG. 4b

- 1 : mecA
- 2: femA Sau
3. femA Sep
4. femA Sho
5. femA Ssa






FIG.5

AMPLIFICATION of CNS SPECIES under UNIVERSAL CONDITIONS.

- (1) : *S. haemolyticus*
- (2) : *S. capitis*
- (3) : *S. cohnii*
- (4) : *S. xylosum*
- (5) : *S. simulans*
- (6) : *S. lugdunensis*
- (7) : *S. schleiferi*
- (8) : *S. warneri*

Th(reaction PCR) = 48°C

.7/20
S. haemolyticus FIG. 6a

10 30 50
ATAATGAAGTTTACAAATTTAACAGCTACAGAGTTTGGCAATTATACAGATAAGATGCCA
MetLysPheThrAsnLeuThrAlaThrGluPheGlyAsnTyrThrAspLysMetPro

70 90 110
TATAGTCATTTACACAAATGACTGAAAATGAGATGAAAGTTGCAAATAAACAGAA
TyrSerHisPheThrGlnMetThrGluAsnTyrGluMetLysValAlaAsnLysThrGlu

130 150 170
ACTCACTTAGTTGGTATAAAAAATAAGATAATGAGGTTATTGCAGCCTGCATGTTGACA
ThrHisLeuValGlyIleLysAsnLysAspAsnGluValIleAlaAlaCysMetLeuThr

190 210 230
GCAGTACCAGTCATGAAATTTTTTAAGTACTTTTATTCTAACCGAGGACCTGTAATTGAT
AlaValProValMetLysPhePheLysTyrPheTyrSerAsnArgGlyProValIleAsp

250 270 290
TATGATAATAGAGAGCTTGTTCACTTTTTCTTTAATGAGTTAACAAAGTATTTAAAACAG
TyrAspAsnArgGluLeuValHisPhePhePheAsnGluLeuThrLysTyrLeuLysGln

310 330 350
CATAATTGCTATATGTTTCGAGTTGACCCTTATTTACCATATCAATATTTAAATCATGAT
HisAsnCysLeuTyrValArgValAspProTyrLeuProTyrGlnTyrLeuAsnHisAsp

370 390 410
GGTGAAATTACAGGTAATGCTGGTAATGATTGGTTCTTTGATAAGATGAAGCATCTCGGA
GlyGluIleThrGlyAsnAlaGlyAsnAspTrpPhePheAspLysMetLysHisLeuGly

430 450 470
TTTGAACATGAAGGCTTTACTAAAGGTTTTGATCCGATTAAACAAATCCGATATCATTCT
PheGluHisGluGlyPheThrLysGlyPheAspProIleLysGlnIleArgTyrHisSer

490 510 530
GTTTTAGATTTAAAAAATAAAACATCTAAAGATATATTAAATGGAATGGATAGTCTACGT
ValLeuAspLeuLysAsnLysThrSerLysAspIleLeuAsnGlyMetAspSerLeuArg

550 570 590
AAACGTAATACTAAAAAAGTTCAAAAAAATGGTGTGAAAGTTAAGTTCTTATCAGAAGAA
LysArgAsnThrLysLysValGlnLysAsnGlyValLysValLysPheLeuSerGluGlu

610 630 650
GAACTTCCAATCTCCGTTTCAATTTATGGAAGATACAACCGAAACGAAAGAATTCCAAGAT
GluLeuProIlePheArgSerPheMetGluAspThrThrGluThrLysGluPheGlnAsp

670 690 710
AGAGATGATAGTTTCTATTATAATCGCTATAGACATTTCAAAGATCACGTGCTTGTACCA
ArgAspAspSerPheTyrTyrAsnArgTyrArgHisPheLysAspHisValLeuValPro

8/20

730	750	770
CTAGCTTATATTAAGTTTGTAGAGTACATCGAAGAATTACAAAATGAACGTGAACTTTA LeuAlaTyrIleLysPheAspGluTyrIleGluGluLeuGlnAsnGluArgGluThrLeu		
790	810	830
AATAAAGATGTTAATAAAGCTTTAAAGATATTGAAAAACGACCAGACAATAAAAGGCA AsnLysAspValAsnLysAlaLeuLysAspIleGluLysArgProAspAsnLysLysAla		
850	870	890
TTTAATAAAAAAGAAAATCTTGAAAAACAATTAGATGCCAATCAACAAAAATTAGACGAG PheAsnLysLysGluAsnLeuGluLysGlnLeuAspAlaAsnGlnGlnLysLeuAspGlu		
910	930	950
GCTAAAAAATTACAAGCCGAACATGGTAATGAATTACCAATTCAGCAGGTTTCTTCTTT AlaLysLysLeuGlnAlaGluHisGlyAsnGluLeuProIleSerAlaGlyPhePhePhe		
970	990	1010
ATTAATCCATTTGAAGTTGTTTATTATGCAGGTGGAACCTCTAATAAATATAGACATTTT IleAsnProPheGluValValTyrTyrAlaGlyGlyThrSerAsnLysTyrArgHisPhe		
1030	1050	1070
GCAGGCAGTTATGCTATTCAATGGACAATGATTAACATGCAATTGATCATGGTATTGAT AlaGlySerTyrAlaIleGlnTrpThrMetIleAsnTyrAlaIleAspHisGlyIleAsp		
1090	1110	1130
AGATACAATTTCTATGGTATTAGCGGTAATTTTAGTGAAGACGCTGAAGATGTTGGAGTC ArgTyrAsnPheTyrGlyIleSerGlyAsnPheSerGluAspAlaGluAspValGlyVal		
1150	1170	1190
ATTAAATTTAAAAAGGTTTCAATGCAGACGTAATTGAGTATGTTGGAGACTTTGTGAAA IleLysPheLysLysGlyPheAsnAlaAspValIleGluTyrValGlyAspPheValLys		
1210	1230	1250
CCTATTAACAAACCTTTGTATTCAAGTGTATAAGACACTCAAAAAGATTAAAAAAGATTT ProIleAsnLysProLeuTyrSerValTyrLysThrLeuLysLysIleLysLysArgPhe		
1270	1290	
AATTAAAGAGGGGAATAGACGAATATGAAATTTACAGAGTTAAAC AsnEndArgGlyGluEndThrAsnMetLysPheThrGluLeuAsn		

FIG. 6b

S. lugdunensisFIG. 7a

10 30 50
ACAGCAAATGAATTCGGTGATTTCACAGATCAAATGCCATATAGTCATTTTACTCAAATG
ThrAlaAsnGluPheGlyAspPheThrAspGlnMetProTyrSerHisPheThrGlnMet

70 90 110
ACAGGTAAGTATAATTTAAAAGTTGCCGAAAAACAGAAACACATTTAGTTGGTGTTAAA
ThrGlyAsnTyrAsnLeuLysValAlaGluLysThrGluThrHisLeuValGlyValLys

130 150 170
AATAATAATAACGAAGTAATTGCAGCATGTTTATTGACAGCTGTACCAGTCATGAAGTTT
AsnAsnAsnAsnGluValIleAlaAlaCysLeuLeuThrAlaValProValMetLysPhe

190 210 230
TTTAAATACTTTTACAGCAATAGAGGCCAGTTATAGATTATGCTAACCAAGAACTTGTA
PheLysTyrPheTyrSerAsnArgGlyProValIleAspTyrAlaAsnGlnGluLeuVal

250 270 290
CATTTTTTCTTTAATGAGCTAACTAAATATTTAAAAAGTATAACTGTCTCTATGTCCGC
HisPhePhePheAsnGluLeuThrLysTyrLeuLysLysTyrAsnCysLeuTyrValArg

310 330 350
ATAGATCCATACTTACCTTATCAATATAGAGACCATGACGGTAATATAACGGCAAATGCT
IleAspProTyrLeuProTyrGlnTyrArgAspHisAspGlyAsnIleThrAlaAsnAla

370 390 410
GGCAATGATTGGTTTTTCAATAAAATGGAACAACCTCGGATACCATCATGATGGCTTTACA
GlyAsnAspTrpPhePheAsnLysMetGluGlnLeuGlyTyrHisHisAspGlyPheThr

430 450 470
ACAGGATTTGATCCAATATTACAAATCAGATTCCATTCTATTCTTAATTTAAAGGATAAG
ThrGlyPheAspProIleLeuGlnIleArgPheHisSerIleLeuAsnLeuLysAspLys

490 510 530
ACAGCTAAAGATGTTTTAAATAATATGGATAGTTTACGTAAAAGAAATACCAAAAAAGT
ThrAlaLysAspValLeuAsnAsnMetAspSerLeuArgLysArgAsnThrLysLysSer

550 570 590
TCAAAAAATGGAGTCAAAGTAAAGTTCCTTACTGAAGAAGAACTACCTATCTTTTCGTTCA
SerLysAsnGlyValLysValLysPheLeuThrGluGluGluLeuProIlePheArgSer

610 630 650
TTTATGGAGCAGACGTCAGAATCTAAAGAATTCTCTGATAGAGACGACCAATTTTATTAC
PheMetGluGlnThrSerGluSerLysGluPheSerAspArgAspAspGlnPheTyrTyr

670 690 710
AATCGGTTTAAAGTACTATAAAGATAGGGTGCTTGTGCCTCTAGCATATTTAAAAATTTGAT
AsnArgPheLysTyrTyrLysAspArgValLeuValProLeuAlaTyrLeuLysPheAsp

10/20

730 750 770
GAATATATAGAAGAACTAACGAATGAACGACAACTTTAGAAAAAGATTTAGGCAAAGCA
GluTyrIleGluGluLeuThrAsnGluArgGlnThrLeuGluLysAspLeuGlyLysAla

790 810 830
CTTAAAGACATTGAGAAACGACCAGATAACAAAAAGCTTATAATAACGAGACAACCTA
LeuLysAspIleGluLysArgProAspAsnLysLysAlaTyrAsnLysArgAspAsnLeu

850 870 890
CAACAACAACTCGATGCCAATCAACAAAAGTTAAATGAGGCTAATCAGTTACAAGCGGAA
GlnGlnGlnLeuAspAlaAsnGlnGlnLysLeuAsnGluAlaAsnGlnLeuGlnAlaGlu

910 930 950
CACGGTAATGAGTTACCTATCTCTGCCGGTTTCTTTATTATTAAATCCGTTTGAAGTTGTA
HisGlyAsnGluLeuProIleSerAlaGlyPhePheIleIleAsnPropheGluValVal

970 990 1010
TACTACGCTGGAGGTACCGCTAATAAATATCGTCATTTTGCAGGTAGTTACGCGGTTTCAG
TyrTyrAlaGlyGlyThrAlaAsnLysTyrArgHisPheAlaGlySerTyrAlaValGln

1030 1050 1070
TGGACTATGATTAACCTATGCTATCGAACACGGCATAGACAGATATAATTTCTACGGCATT
TrpThrMetIleAsnTyrAlaIleGluHisGlyIleAspArgTyrAsnPheTyrGlyIle

1090 1110 1130
AGTGGAACTTCTCAGATGATGCTGAAGACGCAGGTGTCATTTCGCTTTAAAAAAGGTTAT
SerGlyAsnPheSerAspAspAlaGluAspAlaGlyValIleArgPheLysLysGlyTyr

1150 1170 1190
GGTGCAGAAGTGATTGAATACGTTGGTGATTTTGTAAAACCTATAAATAAACCTATGTAT
GlyAlaGluValIleGluTyrValGlyAspPheValLysProIleAsnLysProMetTyr

1210 1230 1250
AAACTTTATTTCAGTGTTAAACGAATTCAAATAAGCTATAGAGGAGAATGGATTAAATTA
LysLeuTyrSerValLeuLysArgIleGlnAsnLysLeuEndArgArgMetAspEndLeu

1270
TGAAATTTACAGAGTTTAAAC
EndAsnLeuGlnSerLeu

FIG. 7b

11/20
S. xylosusFIG. 8a

10 30 50
ACGCAAAAGAGTTTGGGTGCATTTTCAGATAAAATGCCAAATAGCCATTTTCACGCAAATG
ThrGlnLysSerLeuGlyAlaPheSerAspLysMetProAsnSerHisPheThrGlnMet

70 90 110
GTAGGGAATTATGAATTGAAAATTGCAGAAAGTACTGAAACACATTTAGTAGGTATAAAA
ValGlyAsnTyrGluLeuLysIleAlaGluSerThrGluThrHisLeuValGlyIleLys

130 150 170
AACAAATGATAATGAAGTCATTGCAGCTTGTTTATTAACTGCAGTACCAGTAATGAAATTC
AsnAsnAspAsnGluValIleAlaAlaCysLeuLeuThrAlaValProValMetLysPhe

190 210 230
TTTAAGTATTTTTATACTAATAGAGGTCCGGTTATAGATTTTGAAAATAAAGAATTAGTG
PheLysTyrPheTyrThrAsnArgGlyProValIleAspPheGluAsnLysGluLeuVal

250 270 290
CATTACTTTTTCAATGAACCTATCTAAATATGTGAAAAACATAATGCGCTTTATTTAAGA
HisTyrPhePheAsnGluLeuSerLysTyrValLysLysHisAsnAlaLeuTyrLeuArg

310 330 350
GTTGATCCTTATTTAGCATATCAATACCGTAATCATGATGGTGAGGTATTGGAAAATGCA
ValAspProTyrLeuAlaTyrGlnTyrArgAsnHisAspGlyGluValLeuGluAsnAla

370 390 410
GGACATGATTGGATTTTCGATAAAATGAAGCAGCTTGGATATAAACACCAAGGATTTT
GlyHisAspTrpIlePheAspLysMetLysGlnLeuGlyTyrLysHisGlnGlyPheLeu

430 450 470
ACTGGTTTCGATTCAATTATTCAAATTAGGTTCCACTCTGTACTGGATTTAGTAGGTAAA
ThrGlyPheAspSerIleIleGlnIleArgPheHisSerValLeuAspLeuValGlyLys

490 510 530
ACTGCTAAAGATGTACTAAATGGTATGGATAGTTTACGTAAACGTAATACTAAAAAGTA
ThrAlaLysAspValLeuAsnGlyMetAspSerLeuArgLysArgAsnThrLysLysVal

550 570 590
CAAAAAAATGGCGTGAAAGTAAGGTTCTTAAGGGAAGATGAGTTGCCAATTTTCCGTTCA
GlnLysAsnGlyValLysValArgPheLeuArgGluAspGluLeuProIlePheArgSer

610 630 650
TTCATGGAAGATACATCTGAACTAAAGACTTTGACGATAGAGACGATGGCTTTTACTAC
PheMetGluAspThrSerGluThrLysAspPheAspArgAspAspGlyPheTyrTyr

670 690 710
AATAGATTAAGGTATTATAAAGATCGCGTATTAGTACCTCTAGCTTATATGGATTTCAAT
AsnArgLeuArgTyrTyrLysAspArgValLeuValProLeuAlaTyrMetAspPheAsn

730 750 770
GAATATATTGAAGAATTGCAAGCTGAACGTGAGGTGTTAAGCAAAGATATCAATAAAGCA
GluTyrIleGluGluLeuGlnAlaGluArgGluValLeuSerLysAspIleAsnLysAla

790 810 830
GTAAAAGATATCGAGAAAAGACCTGAAAATAAAAAAGCATATAATAAAAAAGATAATCTA
ValLysAspIleGluLysArgProGluAsnLysLysAlaTyrAsnLysLysAspAsnLeu

850 870 890
GAGAAACAACCTTATAGCGAATCAACAAAAAATTGATGAAGCTAAAACTCTACAAGAGAAG
GluLysGlnLeuIleAlaAsnGlnGlnLysIleAspGluAlaLysThrLeuGlnGluLys

910 930 950
CATGGTAACGAACTACCAATCTCAGCAGCATATTTTCATCATTAAACCCTTATGAAGTAGTG
HisGlyAsnGluLeuProIleSerAlaAlaTyrPheIleIleAsnProTyrGluValVal

970 990 1010
TATTATGCGGGTGGAAACGTCAAATGAGTTTAGACATTTTGCTGGTAGTTATGCCATTCAA
TyrTyrAlaGlyGlyThrSerAsnGluPheArgHisPheAlaGlySerTyrAlaIleGln

1030 1050 1070
TGGAAGATGATTAACTATGCTATTGACCATAATATTGATAGATATAATTTTTATGGAATT
TrpLysMetIleAsnTyrAlaIleAspHisAsnIleAspArgTyrAsnPheTyrGlyIle

1090 1110 1130
AGTGGTCATTTTACAGAAGATGCAGAAGATGCCGGTGTAGTTAAATTTAAAAAAGGATTT
SerGlyHisPheThrGluAspAlaGluAspAlaGlyValValLysPheLysLysGlyPhe

1150 1170 1190
AATGCGGATGTAGTGGAATATGTTGGTGATTTTATTAAACCAATCAATAAACCAATGTAC
AsnAlaAspValValGluTyrValGlyAspPheIleLysProIleAsnLysProMetTyr

1210 1230 1250
AAAATTTATACGACATTAAAGAAAATTAAAGATAAAAAAGAAATAAACATTTAATAGAAGG
LysIleTyrThrThrLeuLysLysIleLysAspLysLysLysEndThrPheAsnArgArg

1270 1290
GAACTAAGCTAGAATGAAATTTACAGAGTTAAACC
GluLeuSerEndAsnGluIleTyrArgValLys

FIG. 8b

13/20

S. capitis

FIG. 9a

10 30 50
ACAGCTAAAGAATTTAGTGACTTTACTGATCAAATGCCTTATAGCCATTTTACTCAGATG
ThrAlaLysGluPheSerAspPheThrAspGlnMetProTyrSerHisPheThrGlnMet

70 90 110
GAAGGTAATTATGAACTTAAAGTTGCTGAAGGTACGGATTACATCTCGTAGGAATTAA
GluGlyAsnTyrGluLeuLysValAlaGluGlyThrAspSerHisLeuValGlyIleLys

130 150 170
AATAATGACAACCAAGTGATTGCAGCATGTTTATTAACTGCTGTACCTGTAATGAAAATT
AsnAsnAspAsnGlnValIleAlaAlaCysLeuLeuThrAlaValProValMetLysIle

190 210 230
TTTAAATATTTTTACTCAAATCGCGGGCCAGTGATTGATTATGATAATAAAGAGCTTGTT
PheLysTyrPheTyrSerAsnArgGlyProValIleAspTyrAspAsnLysGluLeuVal

250 270 290
CACTTTTTCTTTAATGAATTAAGTAAATATGTAAAAAAGCATAATTGTCTTTATCTAAGA
HisPhePhePheAsnGluLeuSerLysTyrValLysLysHisAsnCysLeuTyrLeuArg

310 330 350
GTTGACCCCTTATCTTCCTTATCAATACTTAAATCATGACGGTGAAATTATTGGAAATGCT
ValAspProTyrLeuProTyrGlnTyrLeuAsnHisAspGlyGluIleIleGlyAsnAla

370 390 410
GGCCATGATTGGTTTTTCAATAAGATGGAAGAATTAGGATTTGAACATGAAGGCTTTTCAT
GlyHisAspTrpPhePheAsnLysMetGluGluLeuGlyPheGluHisGluGlyPheHis

430 450 470
AAAGGCTTCCATCCTATCTTACAAGTAAGATATCATTTCAGTTTTAGATTTAAAGATAAA
LysGlyPheHisProIleLeuGlnValArgTyrHisSerValLeuAspLeuLysAspLys

490 510 530
ACGGCTAAAGATGTACTCAAAGGAATGGATAGTTTAAAGAAAGCGTAATACTAAGAAAGTA
ThrAlaLysAspValLeuLysGlyMetAspSerLeuArgLysArgAsnThrLysLysVal

550 570 590
CAAAAAAATGGTGTCAAAGTCCGTTTCCTATCCGAAGATGAATTACCTATCTTTAGATCA
GlnLysAsnGlyValLysValArgPheLeuSerGluAspGluLeuProIlePheArgSer

610 630 650
TTTATGGAAGATACTACAGAAACGAAAGAGTTCGCCGATAGAGATGATAGTTTCTATTAT
PheMetGluAspThrThrGluThrLysGluPheAlaAspArgAspAspSerPheTyrTyr

14/20

670 690 710
AATCGATTAAAATACTTTAAAGATAGAGTATTAGTACCATTAGCATATGTTGACTTCGAT
AsnArgLeuLysTyrPheLysAspArgValLeuValProLeuAlaTyrValAspPheAsp

730 750 770
GAGTATATTGAAGAACTTAATAATGAAAGAGATGTTCTTAATAAAGATTTAAATAAGGCG
GluTyrIleGluGluLeuAsnAsnGluArgAspValLeuAsnLysAspLeuAsnLysAla

790 810 830
CTCAAAGATATTGAGAAGAGACCTGATAATAAGAAAAGCTTATAACAAAAGAGATAATCTT
LeuLysAspIleGluLysArgProAspAsnLysLysAlaTyrAsnLysArgAspAsnLeu

850 870 890
CAACAACAATTAGATGCAAATCAACAAAAAATTGATGAAGCTAAAACTTACAACAAGAA
GlnGlnGlnLeuAspAlaAsnGlnGlnLysIleAspGluAlaLysAsnLeuGlnGlnGlu

910 930 950
CATGGTAATGAATTACCTATTTTCAGCTGGATATTTCTTCATTAATCCGTTTGAAGTTGTT
HisGlyAsnGluLeuProIleSerAlaGlyTyrPhePheIleAsnProPheGluValVal

970 990 1010
TATTACGCAGGTGGCACATCGAATCGTTATCGTCACTATGCCGGAAGTTATGCAATTCAA
TyrTyrAlaGlyGlyThrSerAsnArgTyrArgHisTyrAlaGlySerTyrAlaIleGln

1030 1050 1070
TGGAAAATGATAAACTATGCTTTAGAACATGGAATTAACCGTTATAATTTTTATGGAGTT
TrpLysMetIleAsnTyrAlaLeuGluHisGlyIleAsnArgTyrAsnPheTyrGlyVal

1090 1110 1130
AGTGGGGACTTCAGTGAAGACGCTGAAGATGTAGGAGTAATTAAGTTCAAAAAAGGCTAT
SerGlyAspPheSerGluAspAlaGluAspValGlyValIleLysPheLysLysGlyTyr

1150 1170 1190
AATGCTGATGTTATTGAATATGTAGGTGATTTTATCAAGCCAATCAATAAACCTATGTAT
AsnAlaAspValIleGluTyrValGlyAspPheIleLysProIleAsnLysProMetTyr

1210 1230 1250
GCAATCTATAACGCACTTAAAAAGTTAAAGAAATAGATTTTTTTACCAACCCAATTATCT
AlaIleTyrAsnAlaLeuLysLysLeuLysLysEndIlePheLeuProThrGlnLeuSer

1270
AATTATGAAATTTACAGAGTTAA
AsnTyrGluIleTyrArgVal

FIG. 9b

15/20
S. schleiferi

FIG.10a

10 30 50
ACGACGGCTGAATTTGGTGCCTTTACAGATCAAATGCCATATAGCCATTTACGCAAATG
ThrThrAlaGluPheGlyAlaPheThrAspGlnMetProTyrSerHisPheThrGlnMet

70 90 110
GTAGGGAACTATGAATTAAAGGTTGCTGAAGGTGTTGAAACACATCTTGTCGGCATTAAA
ValGlyAsnTyrGluLeuLysValAlaGluGlyValGluThrHisLeuValGlyIleLys

130 150 170
GATAACAACATAACGTACTAGCAGCATGTTTACTGACAGCAGTGCCAGTAATGAAGTTT
AspAsnAsnAsnValLeuAlaAlaCysLeuLeuThrAlaValProValMetLysPhe

190 210 230
TTTAAATATTTTATTCAAACCGCGGACCAGTCTGGAACACGAAAATAAAGAGCTCGTT
PheLysTyrPheTyrSerAsnArgGlyProValMetAspTyrGluAsnLysGluLeuVal

250 270 290
CATTTCTTTTTTAATGAACTTTCAAATATGTTAAGAAATATCACGCATTGTATTTGAGA
HisPhePhePheAsnGluLeuSerLysTyrValLysLysTyrHisAlaLeuTyrLeuArg

310 330 350
GTAGACCCTTATTTACCAATGTTAAAGCGAAACCATGATGGTGAAGTGATTGAAAGATAC
ValAspProTyrLeuProMetLeuLysArgAsnHisAspGlyGluValIleGluArgTyr

370 390 410
GGCAGTGACTGGTTTTTTGATAAAATGGCTGAATTAAACTTTGAACATGAAGGTTTCACA
GlySerAspTrpPhePheAspLysMetAlaGluLeuAsnPheGluHisGluGlyPheThr

430 450 470
ACTGGGTTTTGATACAATAAGGCAAATTCGTTTTTCATTCTGTGCTCGATGTTGAAAATAAA
ThrGlyPheAspThrIleArgGlnIleArgPheHisSerValLeuAspValGluAsnLys

490 510 530
ACATCAAAAGACATCTTAAATCAAATGGATAATTTAAGGAAAAGAAATACGAAAAAAGTA
ThrSerLysAspIleLeuAsnGlnMetAspAsnLeuArgLysArgAsnThrLysLysVal

550 570 590
CAGAAAAATGGTGTGAAAGTCCGCTATCTAAACGAAGATGAATTACATATTTCCGTTTCG
GlnLysAsnGlyValLysValArgTyrLeuAsnGluAspGluLeuHisIlePheArgSer

610 630 650
TTTATGGAAGATACATCTGAAACAAAAGATTTTGTAGATAGAGATGACGATTTTATTAT
PheMetGluAspThrSerGluThrLysAspPheValAspArgAspAspPheTyrTyr

670 690 710
CATCGTATGAAATACTATAAAGATCGTGTCCGCGTACCACTAGCGTATATTGATTTTAAT
HisArgMetLysTyrTyrLysAspArgValArgValProLeuAlaTyrIleAspPheAsn

730 750 770
GCATATTTAGCAGAGCTCAACACTGAAGCGCAAGACTTTAAAAAGAAATTGCAAAAGCA
AlaTyrLeuAlaGluLeuAsnThrGluAlaGlnAspPheLysLysGluIleAlaLysAla

790 810 830
GATAAAGACATCGACAAGCGTCCTGAAAATCAGAAAGCCATAAATAAAAAAGAAAAATTTA
AspLysAspIleAspLysArgProGluAsnGlnLysAlaIleAsnLysLysLysAsnLeu

850 870 890
GAGCAACAACCTAGAAGCGAATCAAGCTAAAATAAAAGAAGCAGAAACATTGCAACTTAAA
GluGlnGlnLeuGluAlaAsnGlnAlaLysIleLysGluAlaGluThrLeuGlnLeuLys

910 930 950
CACGGTGACACATTACCGATTTCGGCTGGATTCTTTATTATTAAATCCATTTGAGGTTGTT
HisGlyAspThrLeuProIleSerAlaGlyPhePheIleIleAsnProPheGluValVal

970 990 1010
TATTATGCAGGCGGCACAGCAAACGAATTTTCGTCATTTTGCTGGAAGCTACGCAGTGCAA
TyrTyrAlaGlyGlyThrAlaAsnGluPheArgHisPheAlaGlySerTyrAlaValGln

1030 1050 1070
TGGGAAATGATTAATTATGCGATTGATTATCAAATTCCTAAGATATAACTTTTATGGCATT
TrpGluMetIleAsnTyrAlaIleAspTyrGlnIleProArgTyrAsnPheTyrGlyIle

1090 1110 1130
AGTGGTGATTTTTTCAGAAGATGCAGAAGATGCAGGTGTGATAAAATTTAAAAAGGCTAT
SerGlyAspPheSerGluAspAlaGluAspAlaGlyValIleLysPheLysLysGlyTyr

1150 1170 1190
AATGCAGAAGTAATAGAATATGTCGGTGATTTTATTAAGCCTATAAACAAACCTGCCTAT
AsnAlaGluValIleGluTyrValGlyAspPheIleLysProIleAsnLysProAlaTyr

1210 1230 1250
ACAGTCTACTTAAATTAAGCAATTAAAGACAAGATAAAAGATAAGATATAGCAAAG
ThrValTyrLeuLysLeuLysGlnLeuLysAspLysIleLysArgEndAspIleAlaLys

1270 1290
AGAAGGGGATTTATTGGTATGAAATTTACAGAGTTAA
ArgArgGlyPheIleGlyMetLysPheThrGluLeu

FIG.10b

S. sciuri 17/20FIG. 11a

10 30 50
ACACTGGAATTTGAAGCTTTTACAAATAAAATGCCGTACGCGCATTTTACACAAGCAGTA
ThrLeuGluPheGluAlaPheThrAsnLysMetProTyrAlaHisPheThrGlnAlaVal

70 90 110
GGTAATTATGAATTAAAAACATCTGAAGGTACTTCAACACATTTAGTAGGGGTCAAAGAT
GlyAsnTyrGluLeuLysThrSerGluGlyThrSerThrHisLeuValGlyValLysAsp

130 150 170
AATCAAGGTGAAGTATTAGCTGCGTGTCTGTTAACAAGTGTACCAGTTATGAAGAAATTT
AsnGlnGlyGluValLeuAlaAlaCysLeuLeuThrSerValProValMetLysLysPhe

190 210 230
AATTACTTTTACTCAAATAGAGGACCAGTAATGGATTATGACAACAAAGAACTTGTGAC
AsnTyrPheTyrSerAsnArgGlyProValMetAspTyrAspAsnLysGluLeuValAsp

250 270 290
TTTTTCTTTAAAGAAATCGTGAGCTATTTAAAAAGTTATAAAGGATTATTCTTTAGAATC
PhePhePheLysGluIleValSerTyrLeuLysSerTyrLysGlyLeuPhePheArgIle

310 330 350
GATCCTTACTTGCCATATCAACTAAGAGATCATGATGGCAATATTAATAAATCATTCAAC
AspProTyrLeuProTyrGlnLeuArgAspHisAspGlyAsnIleLysLysSerPheAsn

370 390 410
CGTGATGGTTTAATTAAACAATTTGAATCATTAGGTTATGAACACCAAGGCTTCACAACT
ArgAspGlyLeuIleLysGlnPheGluSerLeuGlyTyrGluHisGlnGlyPheThrThr

430 450 470
GGTTTCCACCCAATACATCAAATTAGATGGCATTCTGTACTTGATTTAGAAAGTATGGAC
GlyPheHisProIleHisGlnIleArgTrpHisSerValLeuAspLeuGluSerMetAsp

490 510 530
GAAAAGACGCTCATCAAGAACATGGACAGTTTAAGAAAAAGAAATACTAAAAAGTTCAA
GluLysThrLeuIleLysAsnMetAspSerLeuArgLysArgAsnThrLysLysValGln

550 570 590
AAAAATGGTGTAAAGTTCGTTTTCTATCTAAAGATGAAATGCCGATATTCGTCAATTT
LysAsnGlyValLysValArgPheLeuSerLysAspGluMetProIlePheArgGlnPhe

610 630 650
ATGGAAGATACTACAGAGAAGAAAGATTTCAACGATCGTGGCGATGACTTCTATTACAAT
MetGluAspThrThrGluLysLysAspPheAsnAspArgGlyAspAspPheTyrTyrAsn

670 690 710
AGATTAAAATACTTTGAAAATGTAAAGATTCCTTTAGCATATATAGACTTTGAAACTTAC
ArgLeuLysTyrPheGluAsnValLysIleProLeuAlaTyrIleAspPheGluThrTyr

730 750 770
ATTCCACAATTAGAAAAAGAACATGAACAATACAACAAAGATATTGCAAAAGCTGAAAAA
IleProGlnLeuGluLysGluHisGluGlnTyrAsnLysAspIleAlaLysAlaGluLys

790 810 830
GATTTAGAAAAGAAACCAGATAATCAAAAAACGATTAATAAAAATAGACAACTTAAACAA
AspLeuGluLysLysProAspAsnGlnLysThrIleAsnLysIleAspAsnLeuLysGln

850 870 890
CAAAGAGAAGCAAATGAAGCTAAATTAGAAGAAGCACTTCAACTACAACAAGAACATGGT
GlnArgGluAlaAsnGluAlaLysLeuGluGluAlaLeuGlnLeuGlnGlnGluHisGly

910 930 950
GATACATTACCAATAGCAGCTGGTTTCTTTATTATTAATCCATTTGAAGTTGTATATTAT
AspThrLeuProIleAlaAlaGlyPhePheIleIleAsnProPheGluValValTyrTyr

970 990 1010
GCAGGTGGTTCATCGAATGAATATCGTCACCTTGCAGGTAGTTATGCAATTCAGTGGGAA
AlaGlyGlySerSerAsnGluTyrArgHisPheAlaGlySerTyrAlaIleGlnTrpGlu

1030 1050 1070
ATGATTAAATACGCGTTAGATCACAACATTGACCGTTATAACTTCTATGGTATCAGCGGA
MetIleLysTyrAlaLeuAspHisAsnIleAspArgTyrAsnPheTyrGlyIleSerGly

1090 1110 1130
GACTTCTCAGAAGATGCACCTGATGTTGGCGTTATTAAATTTAAAAAAGGTTACAATGCA
AspPheSerGluAspAlaProAspValGlyValIleLysPheLysLysGlyTyrAsnAla

1150 1170 1190
GATGTTTATGAATATATTGGTGATTTTCGTTAAACCAATTAATAAACCAGCGTACAAAGCA
AspValTyrGluTyrIleGlyAspPheValLysProIleAsnLysProAlaTyrLysAla

1210 1230 1250
TATACAACACTAAAAAAGTATTAAAAAATAAATGATTTTCAGTAAGAGAGGAATTTAG
TyrThrThrLeuLysLysValLeuLysLysEndMetIlePheSerLysArgGlyIleEnd

1270
ATAATATGAAATTTACAGAGTTAA
IleIleEndAsnLeuGlnSerEnd

FIG. 11b

Staphylococcus hominis

taaaatttaaattagtcactcaaatcaaatcaaatagagattctaaattagagattatagagataatgaagttttacaaatttaacagactacagaatttggcg 100
M K F T N L T A T E F G D
ATTTTACTGAAAAATGCCATATAGCCATTTTACACAGATGACTGAAATTTATGAGTTTAAAGTTTGTGAGAAAACTGAACTCATTTTAGTAGGAATTA 200
F T E K M P Y S H F T Q M T E N Y E L K V A E K T E T H L V G I K
AAATAAGATAATGAAGTCATTGCTGCTTGATGCTACTGCTGACCCGTTATGAAAAATTTTAAATATTTTATTCAAATCGTGGTCCAGTCATTGAT 300
N K D N E V I A A C M L T A V P V M K I F K Y F Y S N R G P V I D
TATGAAACAAAGAACTCGTTCACTTTTCTTAAACGATTAAGTAATATTTTAAACCAACAACTGTTTATATGACGTATAGACCCCTTATTGCGCTT 400
Y E N K E L V H F F F N E L S K Y L K Q Q H C L Y V R I D P Y L P Y
ATCAATATCGTAATCATGATGATATACAGGAAATCGTGGAAATGATGGTTCTTCGATAAAATGAACAATTAGGATATCAACACGAAGGTTTAC 500
Q Y R N H D G D I T G N A G N D W F F D K M K Q L G Y Q H E G F T
AACAGGATTTGATCCAAATATTACAAATTCGGTTCCATTGATTTTAAATTTAAAGGATAAACTGCTAAAGATGATTAATGGAATGGATGATTACGA 600
T G F D P I L Q I R F H S V L N L K D K T A K D V L N G M D S L R
AAAGAAATTAATAAAAGTCCAAAAATGGTTAAAGTAAGATTTCTTACTAAAGAAATTAACCTATTTTCAGATCATTTTATGGAAGATACATCAG 700
K R N T K K V Q K N G V K V R F L T K E E L P I F R S F M E D T S E
AGACTAAAGAAATTTCTGATAGAGAGGATAGTTTCTTACTATATATCGATTGATCATTTTAAAGATAGAGTATTAGTACCTCTCGCATATATAAAATTTGA 800
T K E F S D R E D S F Y Y N R F D H F K D R V L V P L A Y I K F D
TGAATATCTTGAGAACTTCATGCAGAACGTCAGACATTAAATAAGACTTAAACAAAGCTCTAAAGATATTGAAAAACCGACAGATAACAAAAAGCA 900
E Y L E E L H A E R Q T L N K D L N K A L K D I E K R P D N K K A
CAAAATAAAAAATAAATTTAGAACAGCAATTAAAGCAAAATGAGCAAAATAATGATGAGCAACACAACTTCAATTAGAACATGGTAACGAATTACCAA 1000
Q N K K I N L E Q Q L K A N E Q K I D E A T Q L Q L E H G N E L P I
TATCTGCTGGATTCTTTTATTAATCCATTGGAAGTTGTATATTATGCAGTGGAACTCAATAATATAGACACTTCGCTGGAAGTTATGCAGTTCA 1100
S A G F F F I N P F E V V Y Y A G G T S N K Y R H F A G S Y A V Q
ATGGACTATGATTATGCAATTGATCGCATTCACCGTTTATTAATTTTATGGGATTTAGTGGTCACTTTTACAGATGATGCTGAAGATCGAGGTGT 1200
W T M I N Y A I D H G I D R Y N F Y G I S G H F T D D A E D A G V
GTAAATTTAAAAAGGATTTAATGCAGATGTAATGGAATGATGTTGGTGAATTCGTTAAACCTATAATAAACCAATGATTCATCTACTATATACAACTTA 1300
V K F K K G F N A D V I E Y V G D F V K P I N K P M Y S L Y T T L K
AAAAATTTAAAAAGAGATTGAATTAAGaggggaatagtgagaa 1343
K I K K R L N ///

FIG.12

acttggtttagattagaactcgaaatagaactatagataaaataggagtataataaaaaatgaaatttacgaaatttaacgaaatgaaagatttcgggtg
M K F T N L T A K E F G A

CAATTACGGATAAAAAATGCGGAATAGTCATTTTACGAAATGGTTGGAAATTTATGAATTGAAATTCGAGAAAGTACAGAAACACACACCTAGTAGGTATTAA
F T D K M P N S H F T Q M V G N Y E L K I A E S T E T H L V G I K

GAATAATGATAATGAAGTAATTGCAGCATGTTTACTTACAGCTGTTCTCTGTATGAATTTCTTCAAGTATTTTATTCCAATAGAGGTCCAGTCATAGAT
N N D N E V I A A C L L T A V P V M K F F K Y F Y S N R G P V I D

TTTGGAAAAATAAGAACTCGTACATTACTTCTTTAAACGAANTAGCAAAATATGTAAAAACATATGCTTATATTATTACGAGTAGATCCTTATCTTGCTT
F F E N K E L V H Y F F N E L A K Y V K K H N A L Y L R V D P Y L A Y

ATCAATATCGTAATCATGATGGTAGAGTATTAGCAAAATCGGGTCAGGATTCGATTTTGTATAAATGAACAACTCGGTATTAAGCATGAAGTGTTTTT
Q Y R N N H D G E V L A N A G H D W I F D K M K Q L G Y K H E G F L

AATCGGCTTTGACCCCAATACTTCAATAAGATTCATTTCTGTTTATAGATTTAGCTGGAAAAAACTGCTAAAGACGTACTTAAATGGTATGGATAGTTTACGT
T G F D P I L Q I R F H S V L D L A G K T A K D V L N G M D S L R

AAACGAAATACTFAAAAAAGTACAGAAAAATGGTGTGAAGTAAGATTTTAGGTGAAGTAGAGTTGCCAATATTCGGCTCATTCATCGAAGATACTTCTG
K R N T K K V Q K N G V K V R F L G E D E L P I F R S F M E D T S E

AAACAAGGATTTTGACGATAGATGACGATTTTATTATATAATAGTTAAGATATTATAAAGATCGTGTGCTTGTCCCATTAGCTTATATGGATTTTGA
T K D D F D D R D D F Y Y N R L R Y Y K D R V L V P L A Y M D F D

TGAATATATAACAGAATTAAGGCTGAACGGAAGTATTAAAGTAAAGATATAAATAAGCAGTTAAGGATATAGAAAAAGACCAGAAAAATAAAAAAGCG
E Y I T E L K A E R E V L S K D I N K A V K D I E K R P E N K K A

TATATAAAAAAGAAAAATTTAGAACAACTGATTGCAACCAACCAAAAAATAGATGAAGCCACTCGGTTACAAGAGAGCATGGTAACGAATTTACCGA
Y N K K E N L E-Q Q L I A N Q Q K I D E A T A L Q E K H G N E L P I

TTTCTGCAGCTTACTTTATTATTAATCCTTATGAAGTCGTTTACTATGCAGGTGGTACATCTAAATGAATTTTAGACATTTTGTGTTAGTTATGCAATACA
S A A Y F I I N P Y E V Y Y A G G T S N E F R H F A G S Y A I Q

ATGGAAGATGATTAATTAAGTATAGATATCATATAATAGATAGATATAATTTTATGGTATTAGTGGTCATTTTACTGAAGATGCAGAGATGCAGGTGTT
W K M I N Y A I D H N I D R Y N F Y G I S G H F T E D A E D A G V

GTTAAATTTAAAAAGGTTTTAATGCAGATGTAGAGATATGTTGGTGATTTTATTAAACCGATTAAAGCCAATGTACAAAAATTTATACGACATTGA
V K F K K G F N A D V V E Y V G D F I K P I N K P M Y K I Y T T L K

AAAAAATTAAGGATATAAAAAAGAAAAATAAcataaatagaaaggaaactaagctagaaatgaaatttacagagta

K I K D K K ///

FIG.13

1371

FIG. 13

Page 1

Attorney's Docket I

COPIES DOUBLES

DOCUMENTS ENVOYÉS
AVEC LA LETTRE DU
3/05/2000.

DECLARATION - USA PATENT APPLICAT

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled GENETIC SEQUENCES, DIAGNOSTIC AND/OR QUANTIFICATION METHODS AND DEVICES FOR THE IDENTIFICATION OF STAPHYLOCOCCI STRAINS; the specification of which was internationally filed on September 28, 1998, as International Application No. PCT/BE98/00141, and for which the initial documents for entry into the U.S. National Phase were filed on March 17, 2000, and assigned U.S. Serial No. 09/509,234.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above;

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56;

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATIONPriority
Claimed

No.: 97870146.4

Country: Europe

Date Filed: September 26, 1997

Yes

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.


Full name of first inventor: ¹⁻⁰⁰ Pascal Vannuffel

Inventor's signature

X 

Date

29/09/2000



Page 2

Attorney's Docket No. VANM145.001APC


Residence: **Rue de la Basse Egypte 138, B-7133 Buvrines, BELGIUM**

Citizenship: **Belgium**

BEX

Post Office Address: **Same as Above**

Full name of second inventor: ^{2 id} **Jean-Luc Gala**

Inventor's signature 

Date 29/08/2000

Residence: **Rue Grand Chemin Communal 6, B-5380 Fernelmont, BELGIUM**

Citizenship: **Belgium**

BEX

Post Office Address: **Same as Above**

Send Correspondence To:

Knobbe, Martens, Olson & Bear, LLP

Customer No. 20,995

H:\DOCS\UAH\JAH-2337.DOC
032900

VANM145.001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Vannuffel et al.)
Int'l. App. No. : PCT/BE98/00141)
U.S. Serial No.: 09/509,234)
Int'l. Filed : September 28, 1998)
For : GENETIC SEQUENCES,)
DIAGNOSTIC AND/OR)
QUANTIFICATION METHODS AND)
DEVICES FOR THE)
IDENTIFICATION OF)
STAPHYLOCOCCI STRAINS)
Examiner : Unknown)

ESTABLISHMENT OF RIGHT OF ASSIGNEE TO TAKE ACTION
AND
REVOCATION AND POWER OF ATTORNEY

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The undersigned is empowered to act on behalf of the assignee below (the "Assignee"). A true copy of the original Assignment of the above-captioned application from the inventor(s) to the Assignee is attached hereto. This Assignment represents the entire chain of title of this invention from the Inventor(s) to the Assignee.

I declare that all statements made herein are true, and that all statements made upon information and belief are believed to be true, and further, that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that willful, false statements may jeopardize the validity of the application, or any patent issuing thereon.

Int'l. Application No.: PCT/BE98/00141

App. No.: 09/509,234

Int'l. Filed: September 28, 1998

The undersigned hereby revokes any previous powers of attorney in the subject application, and hereby appoints the registrants of Knobbe, Martens, Olson & Bear, LLP, 620 Newport Center Drive, Sixteenth Floor, Newport Beach, California 92660, Telephone (949) 760-0404, **Customer No. 20,995**, as its attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected herewith. This appointment is to be to the exclusion of the inventor(s) and his attorney(s) in accordance with the provisions of 37 C.F.R. § 3.71.

Please use **Customer No. 20,995** for all communications.

UNIVERSITE CATHOLIQUE DE LOUVAIN

Dated: SEP 14 2000

By: 

Marcel CROCHET

Title: Rector

Address: Halles Universitaires
Place de l'Université 1
B-1348 Louvain-La-Neuve
BELGIUM

MINISTERE DE LA DEFENSE NATIONALE

Dated: 30 Aou 00

By: 

F. CORNELIS

Title:

GenMaj
JSM

Address: Etat Major Général, JSM - R&T
Rue d'Evere 1
B-1140 Bruxelles
BELGIUM